<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS One</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-title-group><journal-title>PLOS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC10732360</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0295934</article-id><article-id pub-id-type="publisher-id">PONE-D-23-10541</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Endocrinology</subject><subj-group><subject>Endocrine Disorders</subject><subj-group><subject>Diabetes Mellitus</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Medical Conditions</subject><subj-group><subject>Metabolic Disorders</subject><subj-group><subject>Diabetes Mellitus</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Epidemiology</subject><subj-group><subject>Medical Risk Factors</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Blood</subject><subj-group><subject>Blood Sugar</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Blood</subject><subj-group><subject>Blood Sugar</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Blood</subject><subj-group><subject>Blood Sugar</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Physiological Parameters</subject><subj-group><subject>Body Weight</subject><subj-group><subject>Body Mass Index</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Health Care</subject><subj-group><subject>Quality of Life</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Social Sciences</subject><subj-group><subject>Sociology</subject><subj-group><subject>Education</subject><subj-group><subject>Educational Attainment</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>People and Places</subject><subj-group><subject>Geographical Locations</subject><subj-group><subject>Asia</subject><subj-group><subject>Indonesia</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>People and Places</subject><subj-group><subject>Geographical Locations</subject><subj-group><subject>Oceania</subject><subj-group><subject>Indonesia</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Endocrinology</subject><subj-group><subject>Endocrine Disorders</subject><subj-group><subject>Diabetes Mellitus</subject><subj-group><subject>Type 2 Diabetes</subject><subj-group><subject>Type 2 Diabetes Risk</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Medical Conditions</subject><subj-group><subject>Metabolic Disorders</subject><subj-group><subject>Diabetes Mellitus</subject><subj-group><subject>Type 2 Diabetes</subject><subj-group><subject>Type 2 Diabetes Risk</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Impaired health-related quality of life due to elevated risk of developing diabetes: A cross-sectional study in Indonesia</article-title><alt-title alt-title-type="running-head">Impaired health-related quality of life and risk of developing diabetes</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0608-3084</contrib-id><name><surname>Rokhman</surname><given-names>M. Rifqi</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref><xref rid="cor001" ref-type="corresp">*</xref></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name><surname>Arifin</surname><given-names>Bustanul</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/visualization/">Visualization</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff004" ref-type="aff">
<sup>4</sup>
</xref><xref rid="aff005" ref-type="aff">
<sup>5</sup>
</xref><xref rid="aff006" ref-type="aff">
<sup>6</sup>
</xref><xref rid="cor001" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Broggi</surname><given-names>Benedetta</given-names></name><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="http://credit.niso.org/contributor-roles/software/">Software</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Verhaar</surname><given-names>Anne-Fleur</given-names></name><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="http://credit.niso.org/contributor-roles/software/">Software</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5395-1892</contrib-id><name><surname>Zulkarnain</surname><given-names>Zulkarnain</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="aff007" ref-type="aff">
<sup>7</sup>
</xref><xref rid="aff008" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Satibi</surname><given-names>Satibi</given-names></name><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Perwitasari</surname><given-names>Dyah Aryani</given-names></name><role content-type="http://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff009" ref-type="aff">
<sup>9</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Boersma</surname><given-names>Cornelis</given-names></name><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="http://credit.niso.org/contributor-roles/visualization/">Visualization</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff010" ref-type="aff">
<sup>10</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Cao</surname><given-names>Qi</given-names></name><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role content-type="http://credit.niso.org/contributor-roles/software/">Software</role><role content-type="http://credit.niso.org/contributor-roles/visualization/">Visualization</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Postma</surname><given-names>Maarten J.</given-names></name><role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role content-type="http://credit.niso.org/contributor-roles/resources/">Resources</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff006" ref-type="aff">
<sup>6</sup>
</xref><xref rid="aff011" ref-type="aff">
<sup>11</sup>
</xref><xref rid="aff012" ref-type="aff">
<sup>12</sup>
</xref><xref rid="aff013" ref-type="aff">
<sup>13</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>van der Schans</surname><given-names>Jurjen</given-names></name><role content-type="http://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/supervision/">Supervision</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff012" ref-type="aff">
<sup>12</sup>
</xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Department of Health Sciences, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Institute of Science in Healthy Ageing &#x00026; HealthcaRE (SHARE), University Medical Center Groningen, University of Groningen, Groningen, The Netherlands</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, Indonesia</addr-line></aff><aff id="aff004"><label>4</label>
<addr-line>Faculty of Pharmacy, Universitas Hasanuddin, Makassar, Indonesia</addr-line></aff><aff id="aff005"><label>5</label>
<addr-line>Disease Prevention and Control Division, Banggai Laut Regency Health, Population Control and Family Planning Service, Central Sulawesi, Indonesia</addr-line></aff><aff id="aff006"><label>6</label>
<addr-line>Unit of Pharmaco Therapy, Epidemiology and Economics (PTE2), Department of Pharmacy, University of Groningen, Groningen, The Netherlands</addr-line></aff><aff id="aff007"><label>7</label>
<addr-line>Faculty of Medicine, Universitas Syiah Kuala, Banda Aceh, Indonesia</addr-line></aff><aff id="aff008"><label>8</label>
<addr-line>Thyroid Center, Zainoel Abidin Hospital, Banda Aceh, Indonesia</addr-line></aff><aff id="aff009"><label>9</label>
<addr-line>Faculty of Pharmacy, Universitas Ahmad Dahlan, Yogyakarta, Indonesia</addr-line></aff><aff id="aff010"><label>10</label>
<addr-line>Faculty of Management Sciences, Open University, Heerlen, The Netherlands</addr-line></aff><aff id="aff011"><label>11</label>
<addr-line>Department of Pharmacology and Therapy, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia</addr-line></aff><aff id="aff012"><label>12</label>
<addr-line>Department of Economics, Econometrics and Finance, Faculty of Economics &#x00026; Business, University of Groningen, Groningen, The Netherlands</addr-line></aff><aff id="aff013"><label>13</label>
<addr-line>Center of Excellence for Pharmaceutical Care Innovation, Universitas Padjadjaran, Bandung, Indonesia</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Purba</surname><given-names>Fredrick Dermawan</given-names></name><role>Editor</role><xref rid="edit1" ref-type="aff"/></contrib></contrib-group><aff id="edit1">
<addr-line>Universitas Padjadjaran, INDONESIA</addr-line>
</aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>MJP reports grants and honoraria from various pharmaceutical companies, including those developing, producing and marketing diabetes drugs. However, all grants and honoraria were fully unrelated to this specific study. The other authors declare that they have no competing interests related to this specific study and topic.</p></fn><corresp id="cor001">* E-mail: <email>r.rokhman@rug.nl</email>, <email>m_rifqi_rokhman@ugm.ac.id</email> (MRR); <email>bustanul.arifin.ury@unhas.ac.id</email>, <email>b.arifin@umcg.nl</email> (BA)</corresp></author-notes><pub-date pub-type="epub"><day>20</day><month>12</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>18</volume><issue>12</issue><elocation-id>e0295934</elocation-id><history><date date-type="received"><day>13</day><month>4</month><year>2023</year></date><date date-type="accepted"><day>4</day><month>12</month><year>2023</year></date></history><permissions><copyright-statement>&#x000a9; 2023 Rokhman et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Rokhman et al</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0295934.pdf"/><abstract><sec id="sec001"><title>Background</title><p>This study investigated the association between elevated risk of developing diabetes and impaired health-related quality of life (HRQoL) in the Indonesian population.</p></sec><sec id="sec002"><title>Methods</title><p>A cross-sectional study was conducted on 1,336 Indonesians from the general population who had no previous diagnosis of diabetes. Utility score to represent HRQoL was measured using the EuroQol 5-dimension, while the risk for developing diabetes was determined using the Finnish Diabetes Risk Score (FINDRISC) instrument. All participants underwent a blood glucose test after fasting for 8 hours. The association between FINDRISC score and HRQoL adjusted for covariates was analysed using multivariate Tobit regression models. Minimal clinically important differences were used to facilitate interpretation of minimal changes in utility score that could be observed.</p></sec><sec id="sec003"><title>Results</title><p>The median (interquartile range) of the overall FINDRISC score was 6 (7), while the mean (95% confidence intervals) of the EQ-5D utility score was 0.93 (0.93&#x02013;0.94). Once adjusted for clinical parameters and socio-demographic characteristics, participants with a higher FINDRISC score showed a significantly lower HRQoL. No significant association was detected between fasting blood glucose level categories and HRQoL. A difference of 4&#x02013;5 points in the FINDRISC score was considered to reflect meaningful change in HRQoL in clinical practice.</p></sec><sec id="sec004"><title>Conclusion</title><p>An elevated risk of developing diabetes is associated with a lower HRQoL. Therefore, attention should be paid not only to patients who have already been diagnosed with diabetes, but also to members of the general population who demonstrate an elevated risk of developing diabetes. This approach will assist in preventing the onset of diabetes and any further deterioration of HRQoL in this segment of the Indonesian population.</p></sec></abstract><funding-group><award-group id="award001"><funding-source>
<institution>LPDP</institution>
</funding-source><award-id>PRJ-1/LPDP.3/2019</award-id><principal-award-recipient>
<contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0608-3084</contrib-id>
<name><surname>Rokhman</surname><given-names>M. Rifqi</given-names></name>
</principal-award-recipient></award-group><award-group id="award002"><funding-source>
<institution>European Union&#x02019;s Horizon 2020</institution>
</funding-source><award-id>825026</award-id><principal-award-recipient>
<name><surname>Postma</surname><given-names>Maarten J.</given-names></name>
</principal-award-recipient></award-group><funding-statement>The research was supported by a grant from the European Union&#x02019;s Horizon 2020 Research and Innovation Programme (SUNI-SEA project) with grant agreement number 825026 and LPDP (the Indonesian Endowment Fund for Education, Ministry of Finance of the Republic of Indonesia) in the form of a Ph.D. scholarship to MRR with grant agreement number PRJ-1/LPDP.3/2019. Funding parties had no role in study design, data collection and analysis, manuscript preparation, or decision to publish.</funding-statement></funding-group><counts><fig-count count="1"/><table-count count="4"/><page-count count="17"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper and its <xref rid="sec021" ref-type="sec">Supporting Information</xref> files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper and its <xref rid="sec021" ref-type="sec">Supporting Information</xref> files.</p></notes></front><body><sec sec-type="intro" id="sec005"><title>Introduction</title><p>The number of people living with diabetes worldwide is predicted to increase by 46% up from 537 million in 2021 to 783 million by 2045 [<xref rid="pone.0295934.ref001" ref-type="bibr">1</xref>]. As one of the most rapidly developing countries in Southeast Asia, Indonesia currently ranks fifth in the number of people with type 2 diabetes (T2D), with more than 19.4 million people with diabetes, and where the prevalence of diabetes in people aged 20&#x02013;79 years has increased from 5.1% in 2011 to 10.8% in 2021 [<xref rid="pone.0295934.ref001" ref-type="bibr">1</xref>, <xref rid="pone.0295934.ref002" ref-type="bibr">2</xref>]. The increase of diabetes diagnoses is further exacerbated by the fact that according to the International Diabetes Federation, there are still more than 14.3 million people living with diabetes undiagnosed in Indonesia [<xref rid="pone.0295934.ref001" ref-type="bibr">1</xref>].</p><p>In tandem with diabetes progression, health-related quality of life (HRQoL) is negatively affected and will reduce [<xref rid="pone.0295934.ref003" ref-type="bibr">3</xref>]. In its early developing stages, diabetes is characterized as an asymptomatic disease, making it difficult for early detection. Consequently, a substantial proportion of the population will have already experienced diabetes complications before a formal diagnosis of diabetes is made [<xref rid="pone.0295934.ref004" ref-type="bibr">4</xref>]. Although previous studies have reported that those with diabetes had significantly poorer HRQoL due to diabetes complications [<xref rid="pone.0295934.ref005" ref-type="bibr">5</xref>, <xref rid="pone.0295934.ref006" ref-type="bibr">6</xref>], HRQoL had already diminished noticeably in individuals who had been detected as having impaired glucose tolerance [<xref rid="pone.0295934.ref003" ref-type="bibr">3</xref>]. Therefore, it is necessary to assess the HRQoL of individuals with normal glucose levels but who are at high-risk for developing diabetes in the future, before they actually develop impaired glucose tolerance.</p><p>Future risk for developing T2D can be assessed using a diabetes risk score by calculating known risk factors of diabetes [<xref rid="pone.0295934.ref007" ref-type="bibr">7</xref>]. This risk score is simple and non-invasive in predicting individuals at elevated risk for developing T2D. Since extending and enhancing a patient&#x02019;s life and life quality is the utmost goal of patient care, HRQoL represents an additional data source for examining clinical outcomes [<xref rid="pone.0295934.ref008" ref-type="bibr">8</xref>, <xref rid="pone.0295934.ref009" ref-type="bibr">9</xref>]. Effectively, even when HRQoL data cannot be obtained directly from an individual, just by estimating the risk of T2D based on a FINDRISC score alone may indirectly provide insight into a patient&#x02019;s HRQoL. From a health economic evaluation perspective, information about the association of estimated risk for developing T2D and impaired HRQoL is crucial for assessing the burden of (pre)diabetes, and in evaluating the benefits of diabetes screening and prevention programs for reducing the burden. Diabetes prevention programs may not only assist to delay or prevent the occurrence of T2D [<xref rid="pone.0295934.ref010" ref-type="bibr">10</xref>], but also improve overall HRQoL to a clinically meaningful degree [<xref rid="pone.0295934.ref011" ref-type="bibr">11</xref>].</p><p>Three previous studies have evaluated the HRQoL in persons with elevated risk of developing diabetes [<xref rid="pone.0295934.ref012" ref-type="bibr">12</xref>&#x02013;<xref rid="pone.0295934.ref014" ref-type="bibr">14</xref>]. These studies reported that people at high-risk for diabetes have a lower HRQoL in comparison with the general population in Finland, Norway, and Latin America. However, very limited studies concerning the link between the elevated risk for developing diabetes and HRQoL currently exist. Only one study in Finland looks at how low HRQoL is significantly associated with an estimated risk of developing T2D [<xref rid="pone.0295934.ref015" ref-type="bibr">15</xref>].</p><p>HRQoL is specific for each country, and no such studies regarding the association of diabetes risk and HRQoL exists for the Asian region. Therefore, this study investigated the association between the risk of developing T2D and HRQoL as adjusted by clinical parameters and socio-demographic characteristics relevant to the Indonesian population, as well as the association between blood glucose level categories and HRQoL.</p></sec><sec sec-type="materials|methods" id="sec006"><title>Materials and methods</title><sec id="sec007"><title>Study design</title><p>A cross-sectional study was carried out in Yogyakarta, Malang (East Java Province) and Banggai Laut Regency (Central Sulawesi Province). Data was collected through questionnaires, measurements of fasting blood glucose, height, weight, and waist circumference from June to November 2019. Three models were developed to investigate associations between risk of developing T2D, covariates, and HRQoL.</p></sec><sec id="sec008"><title>Participants</title><p>Participants for the study were selected if they had never been diagnosed with type 1 or 2 diabetes mellitus, and were at least 18 years of age. Participants were excluded from the study if they were taking any medications that potentially have an effect on blood glucose (such as hydrochlorothiazide and beta-blockers) or if they had medical conditions that could affect blood glucose (such as anorexia).</p><p>In our study, we used a convenience sampling. Upon receiving ethical approval and permission from the Agency for National Unity and Politics to start our data collection, we contacted government authorities, such as village heads, neighbourhood heads, and head office of several institutions. We requested them to announce to the community or their employees that we would conduct our research. Prior to the study, all prospective participants were required to fast for a minimum of 8 hours before the assessment of their fasting blood glucose. We provided brief information of the research objectives, ethics, and procedures of the study to the prospective participants before they decided to join in our study. To avoid bias in measuring fasting blood glucose levels, participants who were not fasting for at least 8 hours were measured the following day.</p><p>Yogyakarta and Malang were categorized as Java area, while Banggai Laut Province was classified as Sulawesi area. For both Java and Sulawesi area, the minimum total sample was 385 participants in accordance with Daniel&#x02019;s sample size formula to determine the sample size for cross-sectional study [<xref rid="pone.0295934.ref016" ref-type="bibr">16</xref>]. Parameters used to determine the minimum sample size were 95% for the level of confidence, 1.96 for the Z<sub>1-&#x003b1;/2</sub> value, 0.5 for the expected proportion, and 0.05 for the absolute error or precision.</p></sec><sec id="sec009"><title>Instruments</title><p>Study instruments consisted of socio-demographic questionnaires, Indonesian language versions of the FINDRISC and EQ-5D-5L, and clinical characteristic forms. Study instruments were completed by the participants, followed by measurements of participants&#x02019; waist circumference, body mass index (BMI) and fasting blood glucose levels by research assistants. Finally, the research assistants checked the study instruments of each participant for completion. Permission to use the FINDRISC instrument was obtained from the American Diabetes Association (ADA) as the copyright owner with document number KL111121-UOG, while permission to use EQ-5D-5L was obtained from the EuroQol research group with registration number 58203.</p></sec><sec id="sec010"><title>Finnish Diabetes Risk Score (FINDRISC)</title><p>The risk of developing T2D was estimated using the FINDRISC instrument. At its conception, FINDRISC was initially developed to detect individuals at future risk of having T2D, but in recent years, the instrument has also been used to identify people with prediabetes and undiagnosed T2D [<xref rid="pone.0295934.ref007" ref-type="bibr">7</xref>, <xref rid="pone.0295934.ref017" ref-type="bibr">17</xref>]. FINDRISC was originally developed for English-speaking populations, but it has since been translated, adapted and validated for Asian populations [<xref rid="pone.0295934.ref018" ref-type="bibr">18</xref>&#x02013;<xref rid="pone.0295934.ref020" ref-type="bibr">20</xref>]. The Indonesian version of this instrument is a preferable diagnostic tool with a good predictive accuracy [<xref rid="pone.0295934.ref021" ref-type="bibr">21</xref>]. The diagnostic accuracy of this Indonesian version indicated by the area under the curve is 0.73 (0.67&#x02013;0.78) for screening undiagnosed T2D, and 0.72 (0.69&#x02013;0.75) for detecting undiagnosed T2D and prediabetes [<xref rid="pone.0295934.ref021" ref-type="bibr">21</xref>]. FINDRISC items and related scoring can be found in <xref rid="pone.0295934.s002" ref-type="supplementary-material">S1 Table</xref>.</p><p>Eight items related to T2D risk factors were included in FINDRISC instrument; namely age, BMI, waist circumference, daily physical activity, fruits and vegetables consumption, use of blood pressure medications, a medical history of high blood glucose, and a family history of diabetes [<xref rid="pone.0295934.ref007" ref-type="bibr">7</xref>]. Each item consists of several answer choices and each with various weighted scores. The FINDRISC total score can range between 0 and 26, of which a higher score indicates a greater risk for developing diabetes.</p><p>The FINDRISC score was categorized in accordance with the original FINDRISC study for developing T2D, and the risk categories comprise of low (&#x0003c;7), slightly elevated (7&#x02013;11), medium (12&#x02013;14), high (15&#x02013;20) and very high (&#x0003e;20). In this study, a modification was made by combining participants in the high-risk and very high-risk categories since only 11 of the 1,336 participants were classified as belonging to the very high-risk category.</p></sec><sec id="sec011"><title>Health-related quality of life (HRQoL)</title><p>HRQoL was estimated using the EuroQol 5-dimension 5-level instrument (EQ-5D-5L). This instrument provides a single, overall health utility score that facilitates the estimation of quality-adjusted life years (QALYs) for health technology assessments. The EQ-5D-5L instrument is a standardized generic instrument to assess HRQoL, and consists of 2 elements [<xref rid="pone.0295934.ref022" ref-type="bibr">22</xref>, <xref rid="pone.0295934.ref023" ref-type="bibr">23</xref>].</p><p>The first element is the descriptive system of EQ-5D-5L that covers 5 dimensions (namely mobility, self-care, usual activities, pain or discomfort, and anxiety or depression), where each dimension has 5 levels of options, ranging from no problems to extreme problems [<xref rid="pone.0295934.ref023" ref-type="bibr">23</xref>]. The second element is the EuroQol Visual Analogue Scale (EQ-VAS) that ranges between 0 (for the worst health state a participants can imagine) and 100 (for the perfect health state). The EQ-5D utility score of a specific health state in the descriptive system can be estimated by combining each level of the five dimensions using a value set, while the EQ-VAS utility score is derived by dividing the number marked on the scale by 100. Both utility scores that calculated from the descriptive system and EQ-VAS ranging from 0 to 1. Participants with a higher utility score represent those with a higher or better quality of life.</p><p>Minimally important differences can be used to facilitate interpretation of minimal changes in the EQ-5D utility score that can be observed in an individual and that are meaningful in clinical practice [<xref rid="pone.0295934.ref024" ref-type="bibr">24</xref>, <xref rid="pone.0295934.ref025" ref-type="bibr">25</xref>]. Thus, in this study, a distribution-based approach was used, and an equation of 0.2*standard deviation is proposed to calculate minimally important differences [<xref rid="pone.0295934.ref025" ref-type="bibr">25</xref>].</p></sec><sec id="sec012"><title>Covariates</title><p>The relationship between FINDRISC score and HRQoL when full covariates were included was calculated with socio-demographic characteristics and clinical parameters as control variables. Socio-demographic data included gender, age, educational level, and study location. We categorized Yogyakarta and Malang as Java. Compared to the Banggai Laut Regency, that is located in a remote area, Malang and Yogyakarta had some similarities in terms of geographical location, accessibility, and health facilities.</p><p>Clinical parameters of participants included BMI, waist circumference, the number of classical diabetes symptoms, and fasting blood glucose level. The weight, height and waist circumference of each participant were measured by qualified research assistants using standard procedures. BMI and waist circumference characteristics were also included upon recommendation by WHO classifications [<xref rid="pone.0295934.ref026" ref-type="bibr">26</xref>, <xref rid="pone.0295934.ref027" ref-type="bibr">27</xref>]. BMI was classified into 4 groups: underweight (BMI &#x0003c;18.5 kg/m<sup>2</sup>), normal (BMI 18.5-&#x0003c;25 kg/m<sup>2</sup>), overweight (BMI 25&#x02013;30 kg/m<sup>2</sup>), and obese (BMI &#x0003e;30 kg/m<sup>2</sup>); while waist circumference was divided into 3 categories based on gender and pursuant to metabolic complication risk: for women (normal &#x0003c;80 cm, increased risk &#x0003e;80&#x02013;88 cm, substantially increased risk &#x0003e;88 cm), while for men (normal &#x0003c;94 cm, increased risk &#x0003e;94&#x02013;102 cm, substantially increased risk &#x0003e;102 cm). Classical diabetes symptoms, and the corresponding numbers, were determined by assessing the presence of polyuria, polyphagia, polydipsia, slow-healing wounds, and blurred vision. Participants were asked whether they experienced blurred vision symptom within the last six months specifically and the last three months for the other classical symptoms of diabetes, of polyuria, polyphagia, polydipsia, and slow-healing wounds.</p><p>The measurement of fasting blood glucose was conducted using a finger-prick test (EasyTouch&#x000ae;GCU) administered by a physician or nurse. Participants were then divided into 3 categories in which as having normal fasting blood glucose (&#x0003c;100 mg/dL), prediabetes (100&#x02013;125 mg/dL) or undiagnosed T2D (&#x0003e;126 mg/dL) following guidelines set by the Indonesian Society of Endocrinology [<xref rid="pone.0295934.ref028" ref-type="bibr">28</xref>].</p></sec><sec id="sec013"><title>Statistical methods</title><p>EQ-5D utility scores were generated using the Indonesian value set [<xref rid="pone.0295934.ref029" ref-type="bibr">29</xref>], and EQ-VAS utility scores were also calculated. The FINDRISC score was reported by using median and interquartile range (IQR), while EQ-5D utility scores were reported using mean and 95% confidence intervals. EQ-5D utility scores were calculated for each group categorized under clinical parameters and sociodemographic characteristics. Mann-Whitney tests were applied to compare EQ-5D utility scores between two groups and not normally distributed, while Kruskal Wallis tests were performed to compare EQ-5D utility scores of more than two groups.</p><p>Logistic regression model was not applied as we did not use dichotomous outcome variables (e.g., yes/no) as our outcomes but HRQoL scores. Also, multivariate linear regression models could not be used since the data was too negatively skewed and not normally distributed, while also an ordinal regression model by dividing the HRQoL based on the percentile values also could not be performed since the 60<sup>th</sup> and 80<sup>th</sup> of percentiles had the same values. In addition, our data had a ceiling effect where 54.3% of participants had perfect health status and EQ-5D utility scores = 1. A Tobit regression model was therefore considered to be the most appropriate approach for our specific dataset to analyse the association between the FINDRISC and HRQoL. The Tobit regression model is used since regression methods can produce biased estimates by not taking into account for the ceiling effect in measuring the health status [<xref rid="pone.0295934.ref030" ref-type="bibr">30</xref>]. Some previous studies especially when analysing the HRQoL with a ceiling effect applied this regression model [<xref rid="pone.0295934.ref031" ref-type="bibr">31</xref>, <xref rid="pone.0295934.ref032" ref-type="bibr">32</xref>]. All FINDRISC items and HRQoL were first assessed and, subsequently, six models were developed to examine associations between FINDRISC scores, socio-demographic characteristics, clinical parameters, and HRQoL.</p><p>In the first model, associations between FINDRISC scores and EQ-5D utility scores were investigated in an unadjusted model, while clinical parameters relating to fasting blood glucose categories were added to the second model. Finally, other clinical parameters and socio-demographic characteristics were added to create a third, most comprehensive model to investigate how the associations changed when adjusting for socio-demographic characteristics (gender, age, educational level, and study location) and other clinical parameters (BMI, waist circumference, the number of classical diabetes symptoms). Associations between FINDRISC scores and EQ-VAS utility scores were also evaluated according to these 3 models. The coefficients for each regression model were displayed together with 95% of confidence intervals. Pseudo r-square values were calculated for each model, and it usually has positive values ranging between 0 and 1. However, in the Tobit regression, the pseudo r-square can also be negative if both values of the constant-only and full model log-likelihoods are positive [<xref rid="pone.0295934.ref033" ref-type="bibr">33</xref>].</p><p>We used complete-case analysis since only 4.8% of total respondents with missing values of their HRQoL. A two-tailed <italic toggle="yes">p-</italic>value of less than .05 was defined as a statistically significant association. Univariate associations were investigated using the Statistical Package for Social Sciences (SPSS) version 26.0, while STATA Special Edition 16.1 was used for all regression analyses.</p></sec><sec id="sec014"><title>Ethical approval</title><p>The research objectives, ethics, and procedures were explained to all potential participants. All individuals participated in the study provided their written informed consent (<xref rid="pone.0295934.s003" ref-type="supplementary-material">S1 File</xref>). Ethical approval was acquired from the Ethics Committee of the Faculty of Dentistry of the Universitas Gadjah Mada Yogyakarta, Indonesia on 25 April 2019 as set out in approval notice 0095. All participants were given health supplements, in particular, iron supplement and multivitamins. Additional information regarding the ethical, cultural, and scientific considerations specific to inclusivity in global research is included in <xref rid="pone.0295934.s004" ref-type="supplementary-material">S1 Checklist</xref>.</p></sec></sec><sec sec-type="results" id="sec015"><title>Results</title><sec id="sec016"><title>Characteristics of study participants</title><p>In total, 1,336 out of 1,403 (95.2%) participants completed the questionnaires (<xref rid="pone.0295934.s001" ref-type="supplementary-material">S1 Dataset</xref>). Two participants (0.2%) were excluded due to negative HRQoL while 65 participants (4.6%) did not have data regarding HRQoL. There were 532 participants (39.8%) from Yogyakarta, 242 participants (18.1%) from Malang, and 562 participants (42.1%) from Banggai Laut. The distribution of participants based on socio-demographic characteristics, clinical parameters, and FINDRISC categories is presented in <xref rid="pone.0295934.t001" ref-type="table">Table 1</xref>. The overall median (IQR) of the FINDRISC score was 6 (7). The number of participants classified to each FINDRISC category was significantly different and, in general, higher FINDRISC categories contained substantially more participants that were women, of older age, a higher BMI and waist circumference, and those who had a higher number of classical diabetes symptoms. In addition, the median (IQR) of fasting blood glucose levels of total participants was 92 mg/dL (IQR = 17). In the categories with a higher FINDRISC score, the median (IQR) fasting blood glucose levels and the percentage of participants with prediabetes and undiagnosed diabetes was significantly higher.</p><table-wrap position="float" id="pone.0295934.t001"><object-id pub-id-type="doi">10.1371/journal.pone.0295934.t001</object-id><label>Table 1</label><caption><title>Distribution of participants in FINDRISC-Indonesian version (n = 1,336).</title></caption><alternatives><graphic xlink:href="pone.0295934.t001" id="pone.0295934.t001g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">Characteristic</th><th align="left" rowspan="2" colspan="1">Group</th><th align="center" rowspan="2" colspan="1">Total (%)</th><th align="center" colspan="4" rowspan="1">FINDRISC category (%)</th><th align="center" rowspan="2" colspan="1"><italic toggle="yes">p</italic>-value</th></tr><tr><th align="center" rowspan="1" colspan="1">Low risk</th><th align="center" rowspan="1" colspan="1">Slightly Elevated risk</th><th align="center" rowspan="1" colspan="1">Moderate risk</th><th align="center" rowspan="1" colspan="1">High risk</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Total participants</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">100.0</td><td align="center" rowspan="1" colspan="1">50.3</td><td align="center" rowspan="1" colspan="1">32.4</td><td align="center" rowspan="1" colspan="1">9.3</td><td align="center" rowspan="1" colspan="1">7.9</td><td align="center" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">Socio-demographic characteristics</italic>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="2" colspan="1">Gender</td><td align="left" rowspan="1" colspan="1">Women</td><td align="center" rowspan="1" colspan="1">61.2</td><td align="center" rowspan="1" colspan="1">54.0</td><td align="center" rowspan="1" colspan="1">68.6</td><td align="center" rowspan="1" colspan="1">66.4</td><td align="center" rowspan="1" colspan="1">74.2</td><td align="center" rowspan="1" colspan="1">&#x0003c; .001</td></tr><tr><td align="left" rowspan="1" colspan="1">Men</td><td align="center" rowspan="1" colspan="1">38.8</td><td align="center" rowspan="1" colspan="1">46.0</td><td align="center" rowspan="1" colspan="1">31.4</td><td align="center" rowspan="1" colspan="1">33.6</td><td align="center" rowspan="1" colspan="1">25.8</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="4" colspan="1">Age</td><td align="left" rowspan="1" colspan="1">&#x0003c;45 years</td><td align="center" rowspan="1" colspan="1">61.8</td><td align="center" rowspan="1" colspan="1">74.5</td><td align="center" rowspan="1" colspan="1">53.9</td><td align="center" rowspan="1" colspan="1">36.9</td><td align="center" rowspan="1" colspan="1">36.6</td><td align="center" rowspan="1" colspan="1">&#x0003c; .001</td></tr><tr><td align="left" rowspan="1" colspan="1">45&#x02013;54 years</td><td align="center" rowspan="1" colspan="1">16.5</td><td align="center" rowspan="1" colspan="1">13.3</td><td align="center" rowspan="1" colspan="1">17.8</td><td align="center" rowspan="1" colspan="1">25.4</td><td align="center" rowspan="1" colspan="1">22.6</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">55&#x02013;64 years</td><td align="center" rowspan="1" colspan="1">11.0</td><td align="center" rowspan="1" colspan="1">6.8</td><td align="center" rowspan="1" colspan="1">14.5</td><td align="center" rowspan="1" colspan="1">18.9</td><td align="center" rowspan="1" colspan="1">16.1</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;64 years</td><td align="center" rowspan="1" colspan="1">10.7</td><td align="center" rowspan="1" colspan="1">5.5</td><td align="center" rowspan="1" colspan="1">13.8</td><td align="center" rowspan="1" colspan="1">18.9</td><td align="center" rowspan="1" colspan="1">24.7</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="4" colspan="1">Education level</td><td align="left" rowspan="1" colspan="1">Up to Junior high school</td><td align="center" rowspan="1" colspan="1">18.3</td><td align="center" rowspan="1" colspan="1">15.6</td><td align="center" rowspan="1" colspan="1">19.4</td><td align="center" rowspan="1" colspan="1">29.5</td><td align="center" rowspan="1" colspan="1">19.4</td><td align="center" rowspan="1" colspan="1">&#x0003c; .001</td></tr><tr><td align="left" rowspan="1" colspan="1">Senior high school</td><td align="center" rowspan="1" colspan="1">29.0</td><td align="center" rowspan="1" colspan="1">31.4</td><td align="center" rowspan="1" colspan="1">25.1</td><td align="center" rowspan="1" colspan="1">29.5</td><td align="center" rowspan="1" colspan="1">28.0</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Undergraduate</td><td align="center" rowspan="1" colspan="1">47.9</td><td align="center" rowspan="1" colspan="1">50.1</td><td align="center" rowspan="1" colspan="1">48.5</td><td align="center" rowspan="1" colspan="1">36.1</td><td align="center" rowspan="1" colspan="1">44.1</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Postgraduate</td><td align="center" rowspan="1" colspan="1">4.8</td><td align="center" rowspan="1" colspan="1">2.9</td><td align="center" rowspan="1" colspan="1">7.0</td><td align="center" rowspan="1" colspan="1">4.9</td><td align="center" rowspan="1" colspan="1">8.6</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="2" colspan="1">Study location</td><td align="left" rowspan="1" colspan="1">Java</td><td align="center" rowspan="1" colspan="1">57.9</td><td align="center" rowspan="1" colspan="1">52.9</td><td align="center" rowspan="1" colspan="1">63.5</td><td align="center" rowspan="1" colspan="1">64.8</td><td align="center" rowspan="1" colspan="1">61.3</td><td align="center" rowspan="1" colspan="1">.002</td></tr><tr><td align="left" rowspan="1" colspan="1">Sulawesi</td><td align="center" rowspan="1" colspan="1">42.1</td><td align="center" rowspan="1" colspan="1">47.1</td><td align="center" rowspan="1" colspan="1">36.5</td><td align="center" rowspan="1" colspan="1">35.2</td><td align="center" rowspan="1" colspan="1">38.7</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">Clinical parameters</italic>
</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="4" colspan="1">Body mass index</td><td align="left" rowspan="1" colspan="1">Underweight (&#x0003c;18.5 kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">7.3</td><td align="center" rowspan="1" colspan="1">12.2</td><td align="center" rowspan="1" colspan="1">2.3</td><td align="center" rowspan="1" colspan="1">1.6</td><td align="center" rowspan="1" colspan="1">1.1</td><td align="center" rowspan="1" colspan="1">&#x0003c; .001</td></tr><tr><td align="left" rowspan="1" colspan="1">Normal (18.5-&#x0003c;25 kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">50.9</td><td align="center" rowspan="1" colspan="1">67.0</td><td align="center" rowspan="1" colspan="1">38.6</td><td align="center" rowspan="1" colspan="1">32.0</td><td align="center" rowspan="1" colspan="1">11.8</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Overweight (25-&#x0003c;30 kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">31.3</td><td align="center" rowspan="1" colspan="1">20.5</td><td align="center" rowspan="1" colspan="1">43.6</td><td align="center" rowspan="1" colspan="1">41.8</td><td align="center" rowspan="1" colspan="1">41.9</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Obese (<underline>&#x0003e;</underline>30 kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">10.5</td><td align="center" rowspan="1" colspan="1">0.3</td><td align="center" rowspan="1" colspan="1">15.5</td><td align="center" rowspan="1" colspan="1">24.6</td><td align="center" rowspan="1" colspan="1">45.2</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="3" colspan="1">Waist circumference</td><td align="left" rowspan="1" colspan="1">Men &#x0003c;94 cm; women &#x0003c;80 cm</td><td align="center" rowspan="1" colspan="1">48.2</td><td align="center" rowspan="1" colspan="1">74.8</td><td align="center" rowspan="1" colspan="1">22.0</td><td align="center" rowspan="1" colspan="1">20.5</td><td align="center" rowspan="1" colspan="1">6.5</td><td align="center" rowspan="1" colspan="1">&#x0003c; .001</td></tr><tr><td align="left" rowspan="1" colspan="1">Men <underline>&#x0003e;</underline>94&#x02013;102 cm; women <underline>&#x0003e;</underline>80&#x02013;88 cm</td><td align="center" rowspan="1" colspan="1">25.1</td><td align="center" rowspan="1" colspan="1">18.2</td><td align="center" rowspan="1" colspan="1">34.4</td><td align="center" rowspan="1" colspan="1">32.8</td><td align="center" rowspan="1" colspan="1">24.7</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Men &#x0003e;102 cm; women &#x0003e;88 cm</td><td align="center" rowspan="1" colspan="1">26.6</td><td align="center" rowspan="1" colspan="1">7.1</td><td align="center" rowspan="1" colspan="1">43.6</td><td align="center" rowspan="1" colspan="1">46.7</td><td align="center" rowspan="1" colspan="1">68.8</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="5" colspan="1">Classical diabetes symptoms</td><td align="left" rowspan="1" colspan="1">No symptoms</td><td align="center" rowspan="1" colspan="1">47.8</td><td align="center" rowspan="1" colspan="1">51.1</td><td align="center" rowspan="1" colspan="1">46.5</td><td align="center" rowspan="1" colspan="1">43.1</td><td align="center" rowspan="1" colspan="1">35.5</td><td align="center" rowspan="1" colspan="1">&#x0003c; .001</td></tr><tr><td align="left" rowspan="1" colspan="1">1 symptom</td><td align="center" rowspan="1" colspan="1">28.9</td><td align="center" rowspan="1" colspan="1">29.4</td><td align="center" rowspan="1" colspan="1">30.2</td><td align="center" rowspan="1" colspan="1">23.6</td><td align="center" rowspan="1" colspan="1">25.8</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">2 symptoms</td><td align="center" rowspan="1" colspan="1">14.5</td><td align="center" rowspan="1" colspan="1">13.1</td><td align="center" rowspan="1" colspan="1">14.0</td><td align="center" rowspan="1" colspan="1">20.3</td><td align="center" rowspan="1" colspan="1">20.4</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">3 symptoms</td><td align="center" rowspan="1" colspan="1">6.1</td><td align="center" rowspan="1" colspan="1">4.5</td><td align="center" rowspan="1" colspan="1">7.2</td><td align="center" rowspan="1" colspan="1">6.5</td><td align="center" rowspan="1" colspan="1">12.9</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;4 symptoms</td><td align="center" rowspan="1" colspan="1">2.3</td><td align="center" rowspan="1" colspan="1">1.9</td><td align="center" rowspan="1" colspan="1">1.4</td><td align="center" rowspan="1" colspan="1">5.7</td><td align="center" rowspan="1" colspan="1">5.4</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="3" colspan="1">Fasting blood glucose</td><td align="left" rowspan="1" colspan="1">Normal (&#x0003c;100 mg/dL)</td><td align="center" rowspan="1" colspan="1">70.8</td><td align="center" rowspan="1" colspan="1">83.9</td><td align="center" rowspan="1" colspan="1">63.7</td><td align="center" rowspan="1" colspan="1">47.5</td><td align="center" rowspan="1" colspan="1">36.6</td><td align="center" rowspan="1" colspan="1">&#x0003c; .001</td></tr><tr><td align="left" rowspan="1" colspan="1">Prediabetes (100&#x02013;125 mg/dL)</td><td align="center" rowspan="1" colspan="1">23.4</td><td align="center" rowspan="1" colspan="1">13.5</td><td align="center" rowspan="1" colspan="1">30.4</td><td align="center" rowspan="1" colspan="1">40.2</td><td align="center" rowspan="1" colspan="1">43.0</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Undiagnosed diabetes (&#x0003e;126 mg/dL)</td><td align="center" rowspan="1" colspan="1">5.8</td><td align="center" rowspan="1" colspan="1">2.6</td><td align="center" rowspan="1" colspan="1">5.9</td><td align="center" rowspan="1" colspan="1">12.3</td><td align="center" rowspan="1" colspan="1">20.4</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Fasting blood glucose, median (IQR)</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">92 (17)</td><td align="center" rowspan="1" colspan="1">89 (15)</td><td align="center" rowspan="1" colspan="1">95 (18)</td><td align="center" rowspan="1" colspan="1">101 (21)</td><td align="center" rowspan="1" colspan="1">104 (22)</td><td align="center" rowspan="1" colspan="1">&#x0003c; .001</td></tr><tr><td align="left" rowspan="1" colspan="1">FINDRISC score, median (IQR)</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">6 (7)</td><td align="center" rowspan="1" colspan="1">3 (4)</td><td align="center" rowspan="1" colspan="1">9 (2)</td><td align="center" rowspan="1" colspan="1">13 (1)</td><td align="center" rowspan="1" colspan="1">16 (3)</td><td align="center" rowspan="1" colspan="1">&#x0003c; .001</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p><italic toggle="yes">Notes</italic>. FINDRISC = Finnish Diabetes Risk Score; IQR = interquartile range;</p></fn><fn id="t001fn002"><p>*<italic toggle="yes">p</italic>-value &#x0003c; .01;</p></fn><fn id="t001fn003"><p>**<italic toggle="yes">p</italic>-value &#x0003c; .001.</p></fn></table-wrap-foot></table-wrap><p>The distribution of the EQ-5D utility scores is shown in <xref rid="pone.0295934.g001" ref-type="fig">Fig 1</xref>, and the overall utility score was determined to be 0.93 (0.93&#x02013;0.94). The HRQoL was significantly lower in women participants (<italic toggle="yes">p</italic> &#x0003c; .001), older (<italic toggle="yes">p</italic> &#x0003c; .001), with higher BMI (<italic toggle="yes">p</italic> = .009), higher numbers of diabetes symptoms (<italic toggle="yes">p</italic> &#x0003c; .001), higher fasting blood glucose levels (<italic toggle="yes">p</italic> &#x0003c; .008), lower formal education levels (<italic toggle="yes">p</italic> &#x0003c; .001), and who resided in Java (<italic toggle="yes">p</italic> = .009). The lowest HRQoL at 0.84 (0.77&#x02013;0.90) was experienced by participants with the highest number of classical diabetes symptoms, while the highest HRQoL at 0.96 (0.93&#x02013;0.98) was found in postgraduate participants.</p><fig position="float" id="pone.0295934.g001"><object-id pub-id-type="doi">10.1371/journal.pone.0295934.g001</object-id><label>Fig 1</label><caption><title>Distribution of participants on EQ-5D utility score (n = 1,336).</title><p><italic toggle="yes">Notes</italic>. 95% CI: 95% confidence interval.</p></caption><graphic xlink:href="pone.0295934.g001" position="float"/></fig></sec><sec id="sec017"><title>The association between FINDRISC components and HRQoL</title><p>The association between FINDRISC components and EQ-5D utility scores is presented in <xref rid="pone.0295934.t002" ref-type="table">Table 2</xref>. All components of FINDRISC had a negative association with EQ-5D utility scores, except for waist circumference (<xref rid="pone.0295934.t002" ref-type="table">Table 2</xref>), which was not significantly associated (<italic toggle="yes">p</italic>-values &#x0003e; .05). FINDRISC items that were significantly associated with EQ-5D utility scores consisted of age (<italic toggle="yes">p</italic> &#x0003c; .001 for participants in 55&#x02013;64 and &#x0003e;64 age groups), BMI (<italic toggle="yes">p</italic> = .012 for participants with BMI &#x0003e;30 kg/m<sup>2</sup>), fruits and vegetables consumption (<italic toggle="yes">p</italic> = .001), and a history of high blood glucose (<italic toggle="yes">p</italic> = .006). Age had the highest negative coefficient, followed by BMI, history of high blood glucose, and fruits and vegetables consumption.</p><table-wrap position="float" id="pone.0295934.t002"><object-id pub-id-type="doi">10.1371/journal.pone.0295934.t002</object-id><label>Table 2</label><caption><title>Association between FINDRISC components and EQ-5D utility scores using multivariate Tobit regression (n = 1,336).</title></caption><alternatives><graphic xlink:href="pone.0295934.t002" id="pone.0295934.t002g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">FINDRISC components</th><th align="center" rowspan="2" colspan="1">Coefficient</th><th align="center" colspan="2" rowspan="1">95% CI</th><th align="center" rowspan="2" colspan="1"><italic toggle="yes">p</italic>-value</th></tr><tr><th align="center" rowspan="1" colspan="1">Lower</th><th align="center" rowspan="1" colspan="1">Upper</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003c; 45 years</td><td align="center" rowspan="1" colspan="1">Ref.</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">45&#x02013;54 years</td><td align="center" rowspan="1" colspan="1">-0.03</td><td align="center" rowspan="1" colspan="1">-0.06</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.01</td><td align="center" rowspan="1" colspan="1">.053</td></tr><tr><td align="left" rowspan="1" colspan="1">55&#x02013;64 years</td><td align="center" rowspan="1" colspan="1">-0.08</td><td align="center" rowspan="1" colspan="1">-0.12</td><td align="center" rowspan="1" colspan="1">-0.05</td><td align="center" rowspan="1" colspan="1">&#x0003c; .001<xref rid="t002fn004" ref-type="table-fn">***</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;64 years</td><td align="center" rowspan="1" colspan="1">-0.15</td><td align="center" rowspan="1" colspan="1">-0.18</td><td align="center" rowspan="1" colspan="1">-0.11</td><td align="center" rowspan="1" colspan="1">&#x0003c; .001<xref rid="t002fn004" ref-type="table-fn">***</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Body mass index</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003c;25 kg/m<sup>2</sup></td><td align="center" rowspan="1" colspan="1">Ref.</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">25&#x02013;30 kg/m<sup>2</sup></td><td align="center" rowspan="1" colspan="1">-0.02</td><td align="center" rowspan="1" colspan="1">-0.04</td><td align="center" rowspan="1" colspan="1">0.01</td><td align="center" rowspan="1" colspan="1">.259</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;30 kg/m<sup>2</sup></td><td align="center" rowspan="1" colspan="1">-0.06</td><td align="center" rowspan="1" colspan="1">-0.10</td><td align="center" rowspan="1" colspan="1">-0.01</td><td align="center" rowspan="1" colspan="1">.012<xref rid="t002fn002" ref-type="table-fn">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Waist circumference</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Men &#x0003c;94 cm; women &#x0003c;80 cm</td><td align="center" rowspan="1" colspan="1">Ref.</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Men <underline>&#x0003e;</underline>94&#x02013;102 cm; women <underline>&#x0003e;</underline>80&#x02013;88 cm</td><td align="center" rowspan="1" colspan="1">0.02</td><td align="center" rowspan="1" colspan="1">-0.01</td><td align="center" rowspan="1" colspan="1">0.05</td><td align="center" rowspan="1" colspan="1">.099</td></tr><tr><td align="left" rowspan="1" colspan="1">Men &#x0003e;102 cm; women &#x0003e;88 cm</td><td align="center" rowspan="1" colspan="1">0.03</td><td align="center" rowspan="1" colspan="1">-0.01</td><td align="center" rowspan="1" colspan="1">0.06</td><td align="center" rowspan="1" colspan="1">.081</td></tr><tr><td align="left" rowspan="1" colspan="1">Physical activity (30 min/day)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">Ref.</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">-0.02</td><td align="center" rowspan="1" colspan="1">-0.05</td><td align="center" rowspan="1" colspan="1">0.01</td><td align="center" rowspan="1" colspan="1">.095</td></tr><tr><td align="left" rowspan="1" colspan="1">Fruit and vegetable consumption</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Every day</td><td align="center" rowspan="1" colspan="1">Ref.</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Not every day</td><td align="center" rowspan="1" colspan="1">-0.04</td><td align="center" rowspan="1" colspan="1">-0.06</td><td align="center" rowspan="1" colspan="1">-0.02</td><td align="center" rowspan="1" colspan="1">.001<xref rid="t002fn003" ref-type="table-fn">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Antihypertensive medication</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Ref.</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">-0.03</td><td align="center" rowspan="1" colspan="1">-0.06</td><td align="center" rowspan="1" colspan="1">0.01</td><td align="center" rowspan="1" colspan="1">.080</td></tr><tr><td align="left" rowspan="1" colspan="1">History of high blood glucose</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Ref.</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Yes</td><td align="center" rowspan="1" colspan="1">-0.05</td><td align="center" rowspan="1" colspan="1">-0.09</td><td align="center" rowspan="1" colspan="1">-0.02</td><td align="center" rowspan="1" colspan="1">.006<xref rid="t002fn003" ref-type="table-fn">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Family members with diabetes</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">No</td><td align="center" rowspan="1" colspan="1">Ref.</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Grandparent, aunt, uncle, or cousin</td><td align="center" rowspan="1" colspan="1">-0.02</td><td align="center" rowspan="1" colspan="1">-0.06</td><td align="center" rowspan="1" colspan="1">0.01</td><td align="center" rowspan="1" colspan="1">.177</td></tr><tr><td align="left" rowspan="1" colspan="1">Parent, brother, sister, or child</td><td align="center" rowspan="1" colspan="1">0.01</td><td align="center" rowspan="1" colspan="1">-0.02</td><td align="center" rowspan="1" colspan="1">0.04</td><td align="center" rowspan="1" colspan="1">.397</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p><italic toggle="yes">Notes</italic>. FINDRISC = Finnish Diabetes Risk Score; Ref: reference;</p></fn><fn id="t002fn002"><p>*<italic toggle="yes">p</italic>-value &#x0003c; .05;</p></fn><fn id="t002fn003"><p>**<italic toggle="yes">p</italic>-value &#x0003c; .01;</p></fn><fn id="t002fn004"><p>***<italic toggle="yes">p</italic>-value &#x0003c; .001.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec018"><title>The association between FINDRISC score, fasting blood glucose category, and HRQoL</title><p>The association between FINDRISC score and EQ-5D utility score is as shown in <xref rid="pone.0295934.t003" ref-type="table">Table 3</xref>. In all three models, FINDRISC scores had significant negative associations with EQ-5D utility scores. Adding socio-demographic characteristics and clinical parameters to the model increased pseudo r-square from 0.05 to 0.33, but only slightly lowered the coefficient of the FINDRISC scores from 0.006 to 0.005. In contrast, the fasting blood glucose category only correlated significantly in Model 2 (<italic toggle="yes">p</italic> = 0.041 for participants with undiagnosed T2D), but the addition of other clinical parameters and socio-demographic characteristics to the model diminished the correlation to the level of insignificance.</p><table-wrap position="float" id="pone.0295934.t003"><object-id pub-id-type="doi">10.1371/journal.pone.0295934.t003</object-id><label>Table 3</label><caption><title>Association between FINDRISC score, clinical conditions, sociodemographic characteristics, and EQ-5D utility score using multivariate Tobit regression analysis (n = 1,336).</title></caption><alternatives><graphic xlink:href="pone.0295934.t003" id="pone.0295934.t003g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">Independent variable</th><th align="left" rowspan="1" colspan="1">Model 1</th><th align="left" rowspan="1" colspan="1">Model 2</th><th align="left" rowspan="1" colspan="1">Model 3</th></tr><tr><th align="left" rowspan="1" colspan="1">pseudo r-square: 0.05</th><th align="left" rowspan="1" colspan="1">pseudo r-square: 0.05</th><th align="left" rowspan="1" colspan="1">pseudo r-square: 0.33</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">FINDRISC score</td><td align="left" rowspan="1" colspan="1">-0.006 (-0.009, -0.004)<xref rid="t003fn004" ref-type="table-fn">***</xref></td><td align="left" rowspan="1" colspan="1">-0.006 (-0.008, -0.003)<xref rid="t003fn004" ref-type="table-fn">***</xref></td><td align="left" rowspan="1" colspan="1">-0.005 (-0.008, -0.002)<xref rid="t003fn003" ref-type="table-fn">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">Clinical parameters</italic>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Fasting blood glucose (vs Normal (&#x0003c;100 mg/dL))</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Prediabetes (100&#x02013;125 mg/dL)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.003 (-0.024, 0.030)</td><td align="left" rowspan="1" colspan="1">0.011 (-0.014, 0.036)</td></tr><tr><td align="left" rowspan="1" colspan="1">Undiagnosed diabetes (&#x0003e;126 mg/dL)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">-0.049 (-0.096, -0.002)<xref rid="t003fn002" ref-type="table-fn">*</xref></td><td align="left" rowspan="1" colspan="1">0.004 (-0.041, 0.048)</td></tr><tr><td align="left" rowspan="1" colspan="1">Body mass index (vs Normal (18.5-&#x0003c;25 kg/m<sup>2</sup>))</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Underweight (&#x0003c;18.5 kg/m<sup>2</sup>)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">-0.029 (-0.069, 0.011)</td></tr><tr><td align="left" rowspan="1" colspan="1">Overweight (25-&#x0003c;30 kg/m<sup>2</sup>)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">-0.027 (-0.054, &#x0003e;-0.001)<xref rid="t003fn002" ref-type="table-fn">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Obese (<underline>&#x0003e;</underline>30 kg/m<sup>2</sup>)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">-0.061 (-0.105, -0.017)<xref rid="t003fn003" ref-type="table-fn">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Waist circumference (vs Men &#x0003c;94 cm; women &#x0003c;80 cm)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Men <underline>&#x0003e;</underline>94&#x02013;102 cm; women <underline>&#x0003e;</underline>80&#x02013;88 cm</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.047 (0.017, 0.077)<xref rid="t003fn003" ref-type="table-fn">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Men &#x0003e;102 cm; women &#x0003e;88 cm</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.074 (0.037, 0.112)<xref rid="t003fn004" ref-type="table-fn">***</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Classical diabetes symptoms (vs No symptoms)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">1 symptom</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">-0.056 (-0.080, -0.032)<xref rid="t003fn004" ref-type="table-fn">***</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">2 symptoms</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">-0.085 (-0.115, -0.054)<xref rid="t003fn004" ref-type="table-fn">***</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">3 symptoms</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">-0.108 (-0.150, -0.066)<xref rid="t003fn004" ref-type="table-fn">***</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><underline>&#x0003e;</underline>4 symptoms</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">-0.137 (-0.202, -0.073)<xref rid="t003fn004" ref-type="table-fn">***</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">Socio-demographic characteristics</italic>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Women (vs Men)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">-0.044 (-0.068, -0.020)<xref rid="t003fn004" ref-type="table-fn">***</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Age (vs &#x0003c;45 years)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">45&#x02013;54 years</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">-0.007 (-0.039, 0.025)</td></tr><tr><td align="left" rowspan="1" colspan="1">55&#x02013;64 years</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">-0.041 (-0.078, -0.003)<xref rid="t003fn002" ref-type="table-fn">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;64 years</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">-0.086 (-0.124, -0.047)<xref rid="t003fn004" ref-type="table-fn">***</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Education (vs Up to Junior high school)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Senior high school</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.051 (0.020, 0.082)<xref rid="t003fn003" ref-type="table-fn">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Undergraduate</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.032 (&#x0003c;0.001, 0.064)<xref rid="t003fn002" ref-type="table-fn">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Postgraduate</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.068 (0.013, 0.124)<xref rid="t003fn002" ref-type="table-fn">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Sulawesi (vs Java)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.005 (-0.023, 0.033)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t003fn001"><p><italic toggle="yes">Notes</italic>. FINDRISC = Finnish Diabetes Risk Score;</p></fn><fn id="t003fn002"><p>*<italic toggle="yes">p</italic>-value &#x0003c; .05;</p></fn><fn id="t003fn003"><p>**<italic toggle="yes">p</italic>-value &#x0003c; .01;</p></fn><fn id="t003fn004"><p>***<italic toggle="yes">p</italic>-value &#x0003c; .001.</p></fn></table-wrap-foot></table-wrap><p>In Model 3, aside from presenting a high FINDRISC score, participants with the lowest EQ-5D utility scores were women, of older age, lower education levels, a higher BMI, lower waist circumferences, and a higher number of classical diabetes symptoms. All variables reduced EQ-5D utility scores except two, namely education levels and waist circumference, which had a positive association. Two variables, namely fasting blood glucose level and living in Java or Sulawesi islands, did not significantly affect HRQoL. The variable with the highest coefficient in negative association with HRQoL was the number of classical diabetes symptoms, which had a coefficient range of 0.056 to 0.137.</p><p>The multivariate association between overall FINDRISC scores and EQ-5D utility scores, using a Tobit regression model, showed that the coefficient of the regression model was -0.0047 (rounded to 0.005 in Model 3) with a standard deviation in the utility scores of 0.10. Therefore, using a minimally important difference of 0.2*standard deviations of the utility score (0.2*0.10 = 0.02) divided by the coefficient, a discrepancy of 4&#x02013;5 points in the FINDRISC score was estimated to provide meaningful changes in quality of life.</p><p><xref rid="pone.0295934.t004" ref-type="table">Table 4</xref> displays negative associations between FINDRISC scores and EQ-VAS in all 3 models. In Model 3, besides FINDRISC score, a significant lower of EQ-VAS was experienced by women participants with underweight, higher education levels, having 3 classical symptoms of diabetes, and participants from Java.</p><table-wrap position="float" id="pone.0295934.t004"><object-id pub-id-type="doi">10.1371/journal.pone.0295934.t004</object-id><label>Table 4</label><caption><title>Association between FINDRISC score, clinical conditions, sociodemographic characteristics, and EQ-VAS using multivariate Tobit regression analysis (n = 1,336).</title></caption><alternatives><graphic xlink:href="pone.0295934.t004" id="pone.0295934.t004g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="2" colspan="1">Independent variable</th><th align="left" rowspan="1" colspan="1">Model 1</th><th align="left" rowspan="1" colspan="1">Model 2</th><th align="left" rowspan="1" colspan="1">Model 3</th></tr><tr><th align="left" rowspan="1" colspan="1">pseudo r-square: -0.024</th><th align="left" rowspan="1" colspan="1">pseudo r-square: -0.032</th><th align="left" rowspan="1" colspan="1">pseudo r-square: -0.275</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">FINDRISC score</td><td align="left" rowspan="1" colspan="1">-0.002 (-0.004, -0.001)<xref rid="t004fn003" ref-type="table-fn">**</xref></td><td align="left" rowspan="1" colspan="1">-0.003 (-0.005, -0.001)<xref rid="t004fn003" ref-type="table-fn">**</xref></td><td align="left" rowspan="1" colspan="1">-0.003 (-0.005, &#x0003e;-0.001)<xref rid="t004fn002" ref-type="table-fn">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">Clinical parameters</italic>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Fasting blood glucose (vs Normal (&#x0003c;100 mg/dL))</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Prediabetes (100&#x02013;125 mg/dL)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.016 (-0.004, 0.036)</td><td align="left" rowspan="1" colspan="1">0.018 (-0.002, 0.038)</td></tr><tr><td align="left" rowspan="1" colspan="1">Undiagnosed diabetes (&#x0003e;126 mg/dL)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.012 (-0.024, 0.048)</td><td align="left" rowspan="1" colspan="1">0.013 (-0.023, 0.049)</td></tr><tr><td align="left" rowspan="1" colspan="1">Body mass index (vs Normal (18.5-&#x0003c;25 kg/m<sup>2</sup>))</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Underweight (&#x0003c;18.5 kg/m<sup>2</sup>)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">-0.048 (-0.080, -0.017)<xref rid="t004fn003" ref-type="table-fn">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Overweight (25-&#x0003c;30 kg/m<sup>2</sup>)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">-0.012 (-0.033, 0.009)</td></tr><tr><td align="left" rowspan="1" colspan="1">Obese (<underline>&#x0003e;</underline>30 kg/m2)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">-0.011 (-0.045, 0.024)</td></tr><tr><td align="left" rowspan="1" colspan="1">Waist circumference (vs Men &#x0003c;94 cm; women &#x0003c;80 cm)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Men <underline>&#x0003e;</underline>94&#x02013;102 cm; women <underline>&#x0003e;</underline>80&#x02013;88 cm</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.020 (-0.003, 0.043)</td></tr><tr><td align="left" rowspan="1" colspan="1">Men &#x0003e;102 cm; women &#x0003e;88 cm</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.015 (-0.014, 0.045)</td></tr><tr><td align="left" rowspan="1" colspan="1">Classical diabetes symptoms (vs No symptoms)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">1 symptom</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.011 (-0.008, 0.029)</td></tr><tr><td align="left" rowspan="1" colspan="1">2 symptoms</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">-0.009 (-0.033, 0.015)</td></tr><tr><td align="left" rowspan="1" colspan="1">3 symptoms</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">-0.052 (-0.086, -0.017)<xref rid="t004fn003" ref-type="table-fn">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><underline>&#x0003e;</underline>4 symptoms</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">-0.020 (-0.074, 0.033)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic toggle="yes">Socio-demographic characteristics</italic>
</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Women (vs Men)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">-0.025 (-0.044, -0.007)<xref rid="t004fn003" ref-type="table-fn">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Age (vs &#x0003c;45 years)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">45&#x02013;54 years</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.009 (-0.016, 0.034)</td></tr><tr><td align="left" rowspan="1" colspan="1">55&#x02013;64 years</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">-0.013 (-0.042, 0.017)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;64 years</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">-0.003 (-0.034, 0.029)</td></tr><tr><td align="left" rowspan="1" colspan="1">Education (vs Up to Junior high school)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Senior high school</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">-0.026 (-0.051, -0.001)<xref rid="t004fn002" ref-type="table-fn">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Undergraduate</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">-0.062 (-0.088, -0.037)<xref rid="t004fn004" ref-type="table-fn">***</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Postgraduate</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">-0.065 (-0.106, -0.023)<xref rid="t004fn003" ref-type="table-fn">**</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Sulawesi (vs Java)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">0.063 (0.041, 0.085)<xref rid="t004fn004" ref-type="table-fn">***</xref></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t004fn001"><p><italic toggle="yes">Notes</italic>. FINDRISC = Finnish Diabetes Risk Score;</p></fn><fn id="t004fn002"><p>*<italic toggle="yes">p</italic>-value &#x0003c; .05;</p></fn><fn id="t004fn003"><p>**<italic toggle="yes">p</italic>-value &#x0003c; .01;</p></fn><fn id="t004fn004"><p>***<italic toggle="yes">p</italic>-value &#x0003c; .001.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="conclusions" id="sec019"><title>Discussion</title><p>This is the first population-based study that examined the association between estimated diabetes risk and impaired HRQoL in an Asian population. A negative association was discovered between FINDRISC scores and HRQoL. This negative association was still significant after clinical parameters and socio-demographic characteristics adjustment. This main finding is confirmed by another study that reported a high risk of diabetes led to a lower HRQoL in Finland [<xref rid="pone.0295934.ref012" ref-type="bibr">12</xref>, <xref rid="pone.0295934.ref015" ref-type="bibr">15</xref>]. In our study, FINDRISC components that were found to be significantly associated with the quality of life comprised of age, BMI, fruits and vegetables consumption, and a history of high blood glucose.</p><p>Since FINDRISC scores had a negative association with EQ-5D utility scores, lowering FINDRISC scores can likely increase HRQoL. FINDRISC contains modifiable risk factors in terms of BMI, waist circumference, daily physical activity, and consumption of fruits and vegetables [<xref rid="pone.0295934.ref007" ref-type="bibr">7</xref>]. These modifiable risk factors are related to each other and can be reduced by implementing public health strategies or promoting lifestyle interventions. A previous meta-analysis showed that dietary and physical activity interventions in South Asians resulted in significant reduction in weight, waist circumference, and diabetes incidence [<xref rid="pone.0295934.ref034" ref-type="bibr">34</xref>], while other studies reported that reduction in weight and waist circumference increased the HRQoL [<xref rid="pone.0295934.ref035" ref-type="bibr">35</xref>&#x02013;<xref rid="pone.0295934.ref037" ref-type="bibr">37</xref>]. Thus, implementing dietary and physical activity interventions as public health strategies will potentially reduce BMI and waist circumference, and increase the HRQoL. Generally, waist circumference has an inverse relationship with the HRQoL; however, in our study, only this variable that positively related to HRQoL. This unique relationship is in accordance with other previous studies that reported higher waist circumference is also a sign of prosperity and better mental health, and when higher waist circumference starts to impair physical function, the HRQoL will begin negatively correlated with waist circumference [<xref rid="pone.0295934.ref038" ref-type="bibr">38</xref>, <xref rid="pone.0295934.ref039" ref-type="bibr">39</xref>].</p><p>Our findings are also corroborated by another study that showed a reduction of 4&#x02013;5 points in FINDRISC score was estimated to provide meaningful improvements, or noticeable changes observed by health care professionals, in the quality of life of individual participants [<xref rid="pone.0295934.ref015" ref-type="bibr">15</xref>]. Notably, while V&#x000e4;&#x000e4;t&#x000e4;inen et al. (2016) used a model without covariates to estimate minimally important differences, our study used a model with an adjustment for covariates. Without a covariate adjustment in our study, a difference of 3&#x02013;4 points in a FINDRISC score would have been estimated to provide noticeable changes in quality of life. This estimation could be used by healthcare professionals in daily practice to inform and encourage participants of diabetes risk-reduction programs.</p><p>Participants with the lowest EQ-5D utility scores were women, older participants, with lower education levels, higher BMI, lower waist circumference, and having a higher number of classical symptoms of diabetes. Together with information about risk of developing diabetes, this information is valuable to formulate the characteristics of target population that might have greatest benefits of intervention to minimize the potential loss of HRQOL and early detection of high-risk patients before they develop impaired glucose tolerance. Previous study shows that subjective health can be improved and risk of T2D and its consequences may be reduced by regular exercise [<xref rid="pone.0295934.ref012" ref-type="bibr">12</xref>]. In our study, individuals with undiagnosed T2D had a utility score of 0.89 (0.85&#x02013;0.92), and this utility score was higher than the utility score of patients with diabetes at 0.77 (0.75&#x02013;0.79) reported in the previous study [<xref rid="pone.0295934.ref006" ref-type="bibr">6</xref>]. In our study, compared to individuals with undiagnosed T2D, individuals with normoglycaemia and prediabetes also had higher utility scores at 0.94 (0.93&#x02013;0.94) and 0.93 (0.92&#x02013;0.94), respectively. This indicates that the quality of life is decreasing over time along with the progression of diabetes.</p><p>Not all predictors associated with lower EQ-5D utility scores were significantly associated with EQ-VAS, namely age, waist circumference, and higher body mass index. This can be the case since EQ-VAS is more sensitive to anchor-point bias when participants interpret the worst or best imaginable health state differently, and as a result, they assign different values for similar health states [<xref rid="pone.0295934.ref040" ref-type="bibr">40</xref>, <xref rid="pone.0295934.ref041" ref-type="bibr">41</xref>] In addition, EQ-VAS reflects more patient perspectives about how good or bad their health, while EQ-5D utility score is more represents the societal perspective and preferable from a health economic point of view [<xref rid="pone.0295934.ref024" ref-type="bibr">24</xref>].</p><p>Higher fasting blood glucose levels were not directly associated with HRQoL when other clinical parameters and socio-demographic characteristics were added to the model. Another study conducted in patients with diabetes in Indonesia also obtained similar findings that random, fasting, and post prandial blood glucose levels did not significantly affect HRQoL [<xref rid="pone.0295934.ref006" ref-type="bibr">6</xref>]. In our model, it is the diabetes-related symptoms variable that has the biggest impact on HRQoL. The early stages of diabetes, commonly referred to as prediabetes, is indicated by a long period and asymptomatic condition of elevated blood glucose levels [<xref rid="pone.0295934.ref042" ref-type="bibr">42</xref>]. This condition causes no complaints, and people with an elevated blood glucose level do not realize they are at risk of developing diabetes. As the condition develops further, the presence of diabetes-related symptoms will significantly lower HRQoL and, unfortunately, only people with pronounced diabetes-related symptoms or complications will seek help from a healthcare provider. This point highlights the importance of screening programs to detect onset or early stages of diabetes and to prevent deterioration in quality of life.</p><p>The strength of this study is the fact that data was collected from three regions across two islands in Indonesia which collectively represent both big cities (Yogyakarta, Malang) and a remote area (Banggai Laut Regency). These three regions were selected due to a notably higher prevalence of community diabetes compared to the national average [<xref rid="pone.0295934.ref043" ref-type="bibr">43</xref>]. so naturally it was predicted that these regions would also see a greater number of people at higher risk for developing diabetes. Moreover, participants in this study covered an extensive range of backgrounds, in term of ages and formal education levels. Concerning age, 61.8% of participants was less than 45 years, 16.5% between 45&#x02013;54 years, 11.0% between 55&#x02013;64 years, and 10.7% more than 64 years. These percentages were similar with the general proportions of Indonesia population based on data from the Central Agency on Statistics in 2019 in which 59.0% of population was between 20&#x02013;45 years, 18.9% between 45&#x02013;54 years, 12.9% between 55&#x02013;64 years, and 9.2% more than 64 years [<xref rid="pone.0295934.ref044" ref-type="bibr">44</xref>].</p><p>Admittedly, some limitations of the study must be acknowledged. Firstly, the study applied a cross-sectional study design that cannot be used to determine causal relationships, and it lacks the ability to track diabetes risk and HRQoL over time. Further studies, using longitudinal study designs, are necessary to reveal the effects of modifiable risk factor intervention for diabetes such as the maintenance of a healthy diet or a lowering of BMI on a participant&#x02019;s HRQoL. Secondly, as Indonesia is not genetically homologous, but rather home to an abundance of Asian ethnicities and ethnic subgroupings, further research to reveal the relationship between diabetes risk and ethnicity is required. Finally, minimally important differences were estimated using a distribution-based approach. Further studies that use a combined approach of a distribution and anchor-based methods are required. This combination method offers the advantages from both anchor-based method by comparing the meaningful changes in HRQoL to external criteria and the benefit from distribution-based method by offering higher stability across different sample [<xref rid="pone.0295934.ref045" ref-type="bibr">45</xref>]. However, this method would require a longitudinal study design with repeated measurements and external criteria as a reference, both of which were not available to us.</p></sec><sec sec-type="conclusions" id="sec020"><title>Conclusions</title><p>Elevated risk for developing diabetes is associated with lower HRQoL, thus individuals with higher FINDRISC score are likely to have lower HRQoL. No association was detected between fasting blood glucose levels and HRQoL. Lower EQ-5D utility scores were also predominantly associated with being older, women, of a lower educational level, a higher BMI, and having a higher number of diabetes symptoms. Therefore, attention should be placed not only on patients with a diabetes diagnosis but also on members of the general population with an elevated risk of developing diabetes to prevent further disease progression and deterioration of HRQoL in such individuals.</p></sec><sec id="sec021" sec-type="supplementary-material"><title>Supporting information</title><supplementary-material id="pone.0295934.s001" position="float" content-type="local-data"><label>S1 Dataset</label><caption><p>(XLSX)</p></caption><media xlink:href="pone.0295934.s001.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="pone.0295934.s002" position="float" content-type="local-data"><label>S1 Table</label><caption><title>Modified FINDRISC- Bahasa Indonesia instrument.</title><p>(DOCX)</p></caption><media xlink:href="pone.0295934.s002.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="pone.0295934.s003" position="float" content-type="local-data"><label>S1 File</label><caption><title>Research protocol.</title><p>(DOCX)</p></caption><media xlink:href="pone.0295934.s003.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="pone.0295934.s004" position="float" content-type="local-data"><label>S1 Checklist</label><caption><title>Inclusivity in global research.</title><p>(DOCX)</p></caption><media xlink:href="pone.0295934.s004.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material id="pone.0295934.s005" position="float" content-type="local-data"><label>S2 Checklist</label><caption><title>STROBE statement&#x02014;checklist of items that should be included in reports of observational studies.</title><p>(DOCX)</p></caption><media xlink:href="pone.0295934.s005.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>We acknowledge the help of all the participants, Prof. Jaakko Tuomilehto (University of Helsinki), Pemerintah Daerah Kabupaten Banggai Laut &#x02010; Sulawesi Tengah [Banggai Laut Regency Regional Administration&#x02013;Central Sulawesi], Muh. Ramlan Budikusuma, Friyanti Zaman, Karsih, Endang Frihatin, Wayan Sadnyana, Trisno Rusli, Nurjanah M Udi, Andi Faizal Fachlevy, Abdul Kahar, Deby Veranasari, Ninda Sari Wahyuningtyas, Putri Pertiwi, Ananda Febrianty, Nurses of Griya Bromo Clinic in Malang, Arly Tania Putri, Dian Pita Sabella, Ni Putu Ayu Crismayani, Febriyanti Siahaan, Sifa Aula Putri, Kresentia Vanda, Saskia, and Merry Yustika. We also acknowledge the Scaling-up NCD Interventions in South-East Asia (SUNI-SEA) project team for their support.</p></ack><ref-list><title>References</title><ref id="pone.0295934.ref001"><label>1</label><mixed-citation publication-type="other">International Diabetes Federation. IDF diabetes atlas tenth edition 2021: Global diabetes data report 2000&#x02013;2045. 2021 [cited 30 Nov 2021]. Available: <ext-link xlink:href="https://diabetesatlas.org/data/en/world/" ext-link-type="uri">https://diabetesatlas.org/data/en/world/</ext-link></mixed-citation></ref><ref id="pone.0295934.ref002"><label>2</label><mixed-citation publication-type="other">International Diabetes Federation. IDF diabetes atlas tenth edition 2021: Indonesia diabetes report 2000&#x02013;2045. 2021 [cited 30 Nov 2021]. Available: <ext-link xlink:href="https://diabetesatlas.org/data/en/country/94/id.html" ext-link-type="uri">https://diabetesatlas.org/data/en/country/94/id.html</ext-link></mixed-citation></ref><ref id="pone.0295934.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>V&#x000e4;&#x000e4;t&#x000e4;inen</surname><given-names>S</given-names></name>, <name><surname>Kein&#x000e4;nen-Kiukaanniemi</surname><given-names>S</given-names></name>, <name><surname>Saramies</surname><given-names>J</given-names></name>, <name><surname>Uusitalo</surname><given-names>H</given-names></name>, <name><surname>Tuomilehto</surname><given-names>J</given-names></name>, <name><surname>Martikainen</surname><given-names>J</given-names></name>. <article-title>Quality of life along the diabetes continuum: A cross-sectional view of health-related quality of life and general health status in middle-aged and older Finns</article-title>. <source>Quality of Life Research</source>. <year>2014</year>;<volume>23</volume>: <fpage>1935</fpage>&#x02013;<lpage>1944</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s11136-014-0638-3</pub-id>
<pub-id pub-id-type="pmid">24510623</pub-id>
</mixed-citation></ref><ref id="pone.0295934.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Brown</surname><given-names>N</given-names></name>, <name><surname>Critchley</surname><given-names>J</given-names></name>, <name><surname>Bogowicz</surname><given-names>P</given-names></name>, <name><surname>Mayige</surname><given-names>M</given-names></name>, <name><surname>Unwin</surname><given-names>N</given-names></name>. <article-title>Risk scores based on self-reported or available clinical data to detect undiagnosed type 2 diabetes: A systematic review</article-title>. <source>Diabetes Res Clin Pract</source>. <year>2012</year>;<volume>98</volume>: <fpage>369</fpage>&#x02013;<lpage>385</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.diabres.2012.09.005</pub-id>
<pub-id pub-id-type="pmid">23010559</pub-id>
</mixed-citation></ref><ref id="pone.0295934.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Mok</surname><given-names>CH</given-names></name>, <name><surname>Kwok</surname><given-names>HHY</given-names></name>, <name><surname>Ng</surname><given-names>CS</given-names></name>, <name><surname>Leung</surname><given-names>GM</given-names></name>, <name><surname>Quan</surname><given-names>J</given-names></name>. <article-title>Health state utility values for type 2 diabetes and related complications in East and Southeast Asia: A systematic review and meta-analysis</article-title>. <source>Value in Health</source>. <year>2021</year>;<volume>24</volume>: <fpage>1059</fpage>&#x02013;<lpage>1067</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jval.2020.12.019</pub-id>
<pub-id pub-id-type="pmid">34243830</pub-id>
</mixed-citation></ref><ref id="pone.0295934.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Arifin</surname><given-names>B</given-names></name>, <name><surname>Idrus</surname><given-names>LR</given-names></name>, <name><surname>van Asselt</surname><given-names>ADI</given-names></name>, <name><surname>Purba</surname><given-names>FD</given-names></name>, <name><surname>Perwitasari</surname><given-names>DA</given-names></name>, <name><surname>Thobari</surname><given-names>JA</given-names></name>, <etal>et al</etal>. <article-title>Health-related quality of life in Indonesian type 2 diabetes mellitus outpatients measured with the Bahasa version of EQ-5D</article-title>. <source>Quality of Life Research</source>. <year>2019</year>;<volume>28</volume>: <fpage>1179</fpage>&#x02013;<lpage>1190</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s11136-019-02105-z</pub-id>
<pub-id pub-id-type="pmid">30649698</pub-id>
</mixed-citation></ref><ref id="pone.0295934.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Lindstr&#x000f6;m</surname><given-names>J</given-names></name>, <name><surname>Tuomilehto</surname><given-names>J</given-names></name>. <article-title>The diabetes risk score: A practical tool to predict type 2 diabetes risk</article-title>. <source>Diabetes Care</source>. <year>2003</year>;<volume>26</volume>: <fpage>725</fpage>&#x02013;<lpage>31</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.2337/diacare.26.3.725</pub-id>
<pub-id pub-id-type="pmid">12610029</pub-id>
</mixed-citation></ref><ref id="pone.0295934.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Thaweethamcharoen</surname><given-names>T</given-names></name>, <name><surname>Srimongkol</surname><given-names>W</given-names></name>, <name><surname>Noparatayaporn</surname><given-names>P</given-names></name>, <name><surname>Jariyayothin</surname><given-names>P</given-names></name>, <name><surname>Sukthinthai</surname><given-names>N</given-names></name>, <name><surname>Aiyasanon</surname><given-names>N</given-names></name>, <etal>et al</etal>. <article-title>Validity and reliability of KDQOL-36 in Thai kidney disease patient</article-title>. <source>Value Health Reg Issues</source>. <year>2013</year>;<volume>2</volume>: <fpage>98</fpage>&#x02013;<lpage>102</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.vhri.2013.02.011</pub-id>
<pub-id pub-id-type="pmid">29702860</pub-id>
</mixed-citation></ref><ref id="pone.0295934.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Sundaram</surname><given-names>M</given-names></name>, <name><surname>Kavookjian</surname><given-names>J</given-names></name>, <name><surname>Patrick</surname><given-names>JH</given-names></name>, <name><surname>Miller</surname><given-names>LA</given-names></name>, <name><surname>Suresh Madhavan</surname><given-names>S</given-names></name>, <name><surname>Scott</surname><given-names>V</given-names></name>. <article-title>Quality of life, health status and clinical outcomes in type 2 diabetes patients</article-title>. <source>Quality of Life Research</source>. <year>2007</year>;<volume>16</volume>: <fpage>165</fpage>&#x02013;<lpage>177</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s11136-006-9105-0</pub-id>
<pub-id pub-id-type="pmid">17033903</pub-id>
</mixed-citation></ref><ref id="pone.0295934.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Uusitupa</surname><given-names>M</given-names></name>, <name><surname>Khan</surname><given-names>T</given-names></name>, <name><surname>Viguiliouk</surname><given-names>E</given-names></name>, <name><surname>Kahleova</surname><given-names>H</given-names></name>. <article-title>Prevention of type 2 diabetes by lifestyle changes: A systematic review and meta-analysis</article-title>. <source>Nutrients</source>. <year>2019</year>;<volume>11</volume>: <fpage>1</fpage>&#x02013;<lpage>22</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.3390/nu11112611</pub-id>
<pub-id pub-id-type="pmid">31683759</pub-id>
</mixed-citation></ref><ref id="pone.0295934.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Karamanakos</surname><given-names>G</given-names></name>, <name><surname>Costa-Pinel</surname><given-names>B</given-names></name>, <name><surname>Gilis-Januszewska</surname><given-names>A</given-names></name>, <name><surname>Velickiene</surname><given-names>D</given-names></name>, <name><surname>Barrio-Torrell</surname><given-names>F</given-names></name>, <name><surname>Cos-Claramunt</surname><given-names>X</given-names></name>, <etal>et al</etal>. <article-title>The effectiveness of a community-based, type 2 diabetes prevention programme on health-related quality of life. The DE-PLAN study</article-title>. <source>PLoS One</source>. <year>2019</year>;<volume>14</volume>: <fpage>1</fpage>&#x02013;<lpage>17</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pone.0221467</pub-id>
<pub-id pub-id-type="pmid">31603914</pub-id>
</mixed-citation></ref><ref id="pone.0295934.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>H&#x000e4;kkinen</surname><given-names>A</given-names></name>, <name><surname>Kukka</surname><given-names>A</given-names></name>, <name><surname>Onatsu</surname><given-names>T</given-names></name>, <name><surname>J&#x0148f;rvenp&#x000e4;&#x000e4;</surname><given-names>S</given-names></name>, <name><surname>Heinonen</surname><given-names>A</given-names></name>, <name><surname>Kyr&#x000f6;l&#x000e4;inen</surname><given-names>H</given-names></name>, <etal>et al</etal>. <article-title>Health-related quality of life and physical activity in persons at high risk for type 2 diabetes</article-title>. <source>Disabil Rehabil</source>. <year>2009</year>;<volume>31</volume>: <fpage>799</fpage>&#x02013;<lpage>805</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1080/08916930802354930</pub-id>
<pub-id pub-id-type="pmid">19034723</pub-id>
</mixed-citation></ref><ref id="pone.0295934.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Nilsen</surname><given-names>V</given-names></name>, <name><surname>Bakke</surname><given-names>PS</given-names></name>, <name><surname>Rohde</surname><given-names>G</given-names></name>, <name><surname>Gallefoss</surname><given-names>F</given-names></name>. <article-title>Predictors of health-related quality of life changes after lifestyle intervention in persons at risk of type 2 diabetes mellitus</article-title>. <source>Quality of Life Research</source>. <year>2014</year>;<volume>23</volume>: <fpage>2585</fpage>&#x02013;<lpage>2593</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s11136-014-0702-z</pub-id>
<pub-id pub-id-type="pmid">24789668</pub-id>
</mixed-citation></ref><ref id="pone.0295934.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Arrieta</surname><given-names>LAA</given-names></name>, <name><surname>Vergara</surname><given-names>TA</given-names></name>, <name><surname>Tuesca</surname><given-names>R</given-names></name>, <name><surname>Acosta</surname><given-names>SR</given-names></name>, <name><surname>Lozano</surname><given-names>KCF</given-names></name>, <name><surname>Aschner</surname><given-names>P</given-names></name>, <etal>et al</etal>. <article-title>Health-related quality of life (HRQoL) in a population at risk of type 2 diabetes: A cross-sectional study in two Latin American cities</article-title>. <source>Health Qual Life Outcomes</source>. <year>2021</year>;<volume>19</volume>: <fpage>1</fpage>&#x02013;<lpage>12</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12955-021-01894-7</pub-id>
<pub-id pub-id-type="pmid">33388064</pub-id>
</mixed-citation></ref><ref id="pone.0295934.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>V&#x000e4;&#x000e4;t&#x000e4;inen</surname><given-names>S</given-names></name>, <name><surname>Cederberg</surname><given-names>H</given-names></name>, <name><surname>Roine</surname><given-names>R</given-names></name>, <name><surname>Kein&#x000e4;nen-Kiukaanniemi</surname><given-names>S</given-names></name>, <name><surname>Saramies</surname><given-names>J</given-names></name>, <name><surname>Uusitalo</surname><given-names>H</given-names></name>, <etal>et al</etal>. <article-title>Does future diabetes risk impair current quality of life? A cross-sectional study of health-related quality of life in relation to the Finnish diabetes risk score (FINDRISC)</article-title>. <source>PLoS One</source>. <year>2016</year>;<volume>11</volume>: <fpage>1</fpage>&#x02013;<lpage>15</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pone.0147898</pub-id>
<pub-id pub-id-type="pmid">26840374</pub-id>
</mixed-citation></ref><ref id="pone.0295934.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Charan</surname><given-names>J</given-names></name>, <name><surname>Biswas</surname><given-names>T</given-names></name>. <article-title>How to calculate sample size for different study designs in medical research?</article-title>
<source>Indian J Psychol Med</source>. <year>2013</year>;<volume>35</volume>: <fpage>121</fpage>&#x02013;<lpage>126</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.4103/0253-7176.116232</pub-id>
<pub-id pub-id-type="pmid">24049221</pub-id>
</mixed-citation></ref><ref id="pone.0295934.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Mavrogianni</surname><given-names>C</given-names></name>, <name><surname>Lambrinou</surname><given-names>CP</given-names></name>, <name><surname>Androutsos</surname><given-names>O</given-names></name>, <name><surname>Lindstr&#x000f6;m</surname><given-names>J</given-names></name>, <name><surname>Kivel&#x000e4;</surname><given-names>J</given-names></name>, <name><surname>Cardon</surname><given-names>G</given-names></name>, <etal>et al</etal>. <article-title>Evaluation of the Finnish Diabetes Risk Score as a screening tool for undiagnosed type 2 diabetes and dysglycaemia among early middle-aged adults in a large-scale European cohort. The Feel4Diabetes-study</article-title>. <source>Diabetes Res Clin Pract</source>. <year>2019</year>;<volume>150</volume>: <fpage>99</fpage>&#x02013;<lpage>110</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.diabres.2019.02.017</pub-id>
<pub-id pub-id-type="pmid">30796939</pub-id>
</mixed-citation></ref><ref id="pone.0295934.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Lim</surname><given-names>HM</given-names></name>, <name><surname>Chia</surname><given-names>YC</given-names></name>, <name><surname>Koay</surname><given-names>ZL</given-names></name>. <article-title>Performance of the Finnish Diabetes Risk Score (FINDRISC) and Modified Asian FINDRISC (ModAsian FINDRISC) for screening of undiagnosed type 2 diabetes mellitus and dysglycaemia in primary care</article-title>. <source>Prim Care Diabetes</source>. <year>2020</year>;<volume>14</volume>: <fpage>494</fpage>&#x02013;<lpage>500</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.pcd.2020.02.008</pub-id>
<pub-id pub-id-type="pmid">32156516</pub-id>
</mixed-citation></ref><ref id="pone.0295934.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>M</given-names></name>, <name><surname>Zhang</surname><given-names>H</given-names></name>, <name><surname>Wang</surname><given-names>C</given-names></name>, <name><surname>Ren</surname><given-names>Y</given-names></name>, <name><surname>Wang</surname><given-names>B</given-names></name>, <name><surname>Zhang</surname><given-names>L</given-names></name>, <etal>et al</etal>. <article-title>Development and validation of a risk-score model for type 2 diabetes: A cohort study of a rural adult Chinese population</article-title>. <source>PLoS One</source>. <year>2016</year>;<volume>11</volume>: <fpage>1</fpage>&#x02013;<lpage>13</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pone.0152054</pub-id>
<pub-id pub-id-type="pmid">27070555</pub-id>
</mixed-citation></ref><ref id="pone.0295934.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Dugee</surname><given-names>O</given-names></name>, <name><surname>Janchiv</surname><given-names>O</given-names></name>, <name><surname>Jousilahti</surname><given-names>P</given-names></name>, <name><surname>Sakhiya</surname><given-names>A</given-names></name>, <name><surname>Palam</surname><given-names>E</given-names></name>, <name><surname>Nuorti</surname><given-names>JP</given-names></name>, <etal>et al</etal>. <article-title>Adapting existing diabetes risk scores for an Asian population: A risk score for detecting undiagnosed diabetes in the Mongolian population</article-title>. <source>BMC Public Health</source>. <year>2015</year>;<volume>15</volume>: <fpage>1</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12889-015-2298-9</pub-id>
<pub-id pub-id-type="pmid">25563658</pub-id>
</mixed-citation></ref><ref id="pone.0295934.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Rokhman</surname><given-names>MR</given-names></name>, <name><surname>Arifin</surname><given-names>B</given-names></name>, <name><surname>Zulkarnain</surname><given-names>Z</given-names></name>, <name><surname>Satibi</surname><given-names>S</given-names></name>, <name><surname>Perwitasari</surname><given-names>DA</given-names></name>, <name><surname>Boersma</surname><given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Adaptation and validation of the Finnish Diabetes Risk Score for detecting undiagnosed diabetes and dysglycaemia in the Indonesian population</article-title>. <source>PLoS One</source>. <year>2022</year>;<volume>17</volume>: <fpage>1</fpage>&#x02013;<lpage>16</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1371/journal.pone.0269853</pub-id>
<pub-id pub-id-type="pmid">35862370</pub-id>
</mixed-citation></ref><ref id="pone.0295934.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Herdman</surname><given-names>M</given-names></name>, <name><surname>Gudex</surname><given-names>C</given-names></name>, <name><surname>Lloyd</surname><given-names>A</given-names></name>, <name><surname>Janssen</surname><given-names>M</given-names></name>, <name><surname>Kind</surname><given-names>P</given-names></name>, <name><surname>Parkin</surname><given-names>D</given-names></name>, <etal>et al</etal>. <article-title>Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)</article-title>. <source>Quality of Life Research</source>. <year>2011</year>;<volume>20</volume>: <fpage>1727</fpage>&#x02013;<lpage>1736</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s11136-011-9903-x</pub-id>
<pub-id pub-id-type="pmid">21479777</pub-id>
</mixed-citation></ref><ref id="pone.0295934.ref023"><label>23</label><mixed-citation publication-type="other">EuroQol Research Foundation. EQ-5D-5L user guide. Version 3.0. Rotterdam, the Netherlands; 2019. Available: <ext-link xlink:href="https://euroqol.org/publications/user-guides/" ext-link-type="uri">https://euroqol.org/publications/user-guides/</ext-link></mixed-citation></ref><ref id="pone.0295934.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Luo</surname><given-names>N</given-names></name>, <name><surname>Johnson</surname><given-names>JA</given-names></name>, <name><surname>Coons</surname><given-names>SJ</given-names></name>. <article-title>Using instrument-defined health state transitions to estimate minimally important differences for four preference-based health-related quality of life instruments</article-title>. <source>Med Care</source>. <year>2010</year>;<volume>48</volume>: <fpage>365</fpage>&#x02013;<lpage>371</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1097/mlr.0b013e3181c162a2</pub-id>
<pub-id pub-id-type="pmid">20355266</pub-id>
</mixed-citation></ref><ref id="pone.0295934.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Fayers</surname><given-names>PM</given-names></name>, <name><surname>Hays</surname><given-names>RD</given-names></name>. <article-title>Don&#x02019;t middle your MIDs: Regression to the mean shrinks estimates of minimally important differences</article-title>. <source>Quality of Life Research</source>. <year>2014</year>;<volume>23</volume>: <fpage>1</fpage>&#x02013;<lpage>4</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s11136-013-0443-4</pub-id>
<pub-id pub-id-type="pmid">23722635</pub-id>
</mixed-citation></ref><ref id="pone.0295934.ref026"><label>26</label><mixed-citation publication-type="other">World Health Organization. Obesity: Preventing and managing the global epidemic. Geneva: WHO; 2000. doi:10.1007/BF00400469</mixed-citation></ref><ref id="pone.0295934.ref027"><label>27</label><mixed-citation publication-type="other">World Health Organization. Waist circumference and waist-hip ratio: Report of a WHO expert consultation. Geneva: WHO; 2008. Available: <ext-link xlink:href="https://apps.who.int/iris/handle/10665/44583" ext-link-type="uri">https://apps.who.int/iris/handle/10665/44583</ext-link></mixed-citation></ref><ref id="pone.0295934.ref028"><label>28</label><mixed-citation publication-type="other">Perkeni. Pedoman pengelolaan dan pencegahan diabetes melitus tipe 2 di Indonesia 2021. PB Perkeni; 2021. Available: <ext-link xlink:href="https://pbperkeni.or.id/wp-content/uploads/2021/11/22-10-21-Website-Pedoman-Pengelolaan-dan-Pencegahan-DMT2-Ebook.pdf" ext-link-type="uri">https://pbperkeni.or.id/wp-content/uploads/2021/11/22-10-21-Website-Pedoman-Pengelolaan-dan-Pencegahan-DMT2-Ebook.pdf</ext-link></mixed-citation></ref><ref id="pone.0295934.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Purba</surname><given-names>FD</given-names></name>, <name><surname>Hunfeld</surname><given-names>JAM</given-names></name>, <name><surname>Iskandarsyah</surname><given-names>A</given-names></name>, <name><surname>Fitriana</surname><given-names>TS</given-names></name>, <name><surname>Sadarjoen</surname><given-names>SS</given-names></name>, <name><surname>Ramos-Go&#x000f1;i</surname><given-names>JM</given-names></name>, <etal>et al</etal>. <article-title>The Indonesian EQ-5D-5L value set</article-title>. <source>Pharmacoeconomics</source>. <year>2017</year>;<volume>35</volume>: <fpage>1153</fpage>&#x02013;<lpage>1165</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s40273-017-0538-9</pub-id>
<pub-id pub-id-type="pmid">28695543</pub-id>
</mixed-citation></ref><ref id="pone.0295934.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Austin</surname><given-names>PC</given-names></name>. <article-title>Bayesian extensions of the tobit model for analyzing measures of health status</article-title>. <source>Medical Decision Making</source>. <year>2002</year>;<volume>22</volume>: <fpage>152</fpage>&#x02013;<lpage>162</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1177/0272989X0202200212</pub-id>
<pub-id pub-id-type="pmid">11958497</pub-id>
</mixed-citation></ref><ref id="pone.0295934.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Tran</surname><given-names>BX</given-names></name>, <name><surname>Ohinmaa</surname><given-names>A</given-names></name>, <name><surname>Nguyen</surname><given-names>LT</given-names></name>. <article-title>Quality of life profile and psychometric properties of the EQ-5D-5L in HIV/AIDS patients</article-title>. <source>Health Qual Life Outcomes</source>. <year>2012</year>;<volume>10</volume>: <fpage>1</fpage>&#x02013;<lpage>8</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/1477-7525-10-132</pub-id>
<pub-id pub-id-type="pmid">22208808</pub-id>
</mixed-citation></ref><ref id="pone.0295934.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Wong</surname><given-names>ELY</given-names></name>, <name><surname>Xu</surname><given-names>RH</given-names></name>, <name><surname>Cheung</surname><given-names>AWL</given-names></name>. <article-title>Health-related quality of life among patients with hypertension: Population-based survey using EQ-5D-5L in Hong Kong SAR, China</article-title>. <source>BMJ Open</source>. <year>2019</year>;<volume>9</volume>: <fpage>1</fpage>&#x02013;<lpage>10</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1136/bmjopen-2019-032544</pub-id>
<pub-id pub-id-type="pmid">31562165</pub-id>
</mixed-citation></ref><ref id="pone.0295934.ref033"><label>33</label><mixed-citation publication-type="other">Sribney W, StataCorp. Why is the pseudo-R2 for tobit negative or greater than one? [cited 21 Sep 2023]. Available: <ext-link xlink:href="https://www.stata.com/support/faqs/statistics/pseudo-r2/" ext-link-type="uri">https://www.stata.com/support/faqs/statistics/pseudo-r2/</ext-link></mixed-citation></ref><ref id="pone.0295934.ref034"><label>34</label><mixed-citation publication-type="book"><name><surname>Jenum</surname><given-names>AK</given-names></name>, <name><surname>Brekke</surname><given-names>I</given-names></name>, <name><surname>Mdala</surname><given-names>I</given-names></name>, <name><surname>Muilwijk</surname><given-names>M</given-names></name>, <name><surname>Ramachandran</surname><given-names>A</given-names></name>, <name><surname>Kj&#x000f8;llesdal</surname><given-names>M</given-names></name>, <etal>et al</etal>. <part-title>Effects of dietary and physical activity interventions on the risk of type 2 diabetes in South Asians: Meta-analysis of individual participant data from randomised controlled trials</part-title>. <source>Diabetologia</source>. <publisher-name>Springer Verlag</publisher-name>; <year>2019</year>. pp. <fpage>1337</fpage>&#x02013;<lpage>1348</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s00125-019-4905-2</pub-id>
</mixed-citation></ref><ref id="pone.0295934.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Stephenson</surname><given-names>J</given-names></name>, <name><surname>Smith</surname><given-names>CM</given-names></name>, <name><surname>Kearns</surname><given-names>B</given-names></name>, <name><surname>Haywood</surname><given-names>A</given-names></name>, <name><surname>Bissell</surname><given-names>P</given-names></name>. <article-title>The association between obesity and quality of life: A retrospective analysis of a large-scale population-based cohort study</article-title>. <source>BMC Public Health</source>. <year>2021</year>;<volume>21</volume>: <fpage>1</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12889-021-12009-8</pub-id>
<pub-id pub-id-type="pmid">33388037</pub-id>
</mixed-citation></ref><ref id="pone.0295934.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Kearns</surname><given-names>B</given-names></name>, <name><surname>Ara</surname><given-names>R</given-names></name>, <name><surname>Young</surname><given-names>T</given-names></name>, <name><surname>Relton</surname><given-names>C</given-names></name>. <article-title>Association between body mass index and health-related quality of life, and the impact of self-reported long-term conditions &#x02010; Cross-sectional study from the south Yorkshire cohort dataset</article-title>. <source>BMC Public Health</source>. <year>2013</year>;<volume>13</volume>: <fpage>1</fpage>&#x02013;<lpage>11</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/1471-2458-13-1009</pub-id>
<pub-id pub-id-type="pmid">23280303</pub-id>
</mixed-citation></ref><ref id="pone.0295934.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Kolotkin</surname><given-names>RL</given-names></name>, <name><surname>Andersen</surname><given-names>JR</given-names></name>. <article-title>A systematic review of reviews: exploring the relationship between obesity, weight loss and health-related quality of life</article-title>. <source>Clinical Obesity</source>. <year>2017</year>. pp. <fpage>273</fpage>&#x02013;<lpage>289</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/cob.12203</pub-id>
<pub-id pub-id-type="pmid">28695722</pub-id>
</mixed-citation></ref><ref id="pone.0295934.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>You</surname><given-names>H</given-names></name>, <name><surname>Li</surname><given-names>XL</given-names></name>, <name><surname>Jing</surname><given-names>KZ</given-names></name>, <name><surname>Li</surname><given-names>ZG</given-names></name>, <name><surname>Cao</surname><given-names>HM</given-names></name>, <name><surname>Wang</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Association between body mass index and health-related quality of life among Chinese elderly &#x02010; Evidence from a community-based study</article-title>. <source>BMC Public Health</source>. <year>2018</year>;<volume>18</volume>: <fpage>1</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12889-018-6086-1</pub-id>
<pub-id pub-id-type="pmid">30314493</pub-id>
</mixed-citation></ref><ref id="pone.0295934.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Wu</surname><given-names>S</given-names></name>, <name><surname>Wang</surname><given-names>R</given-names></name>, <name><surname>Jiang</surname><given-names>A</given-names></name>, <name><surname>Ding</surname><given-names>Y</given-names></name>, <name><surname>Wu</surname><given-names>M</given-names></name>, <name><surname>Ma</surname><given-names>X</given-names></name>, <etal>et al</etal>. <article-title>Abdominal obesity and its association with health-related quality of life in adults: A population-based study in five Chinese cities</article-title>. <source>Health Qual Life Outcomes</source>. <year>2014</year>;<volume>12</volume>: <fpage>1</fpage>&#x02013;<lpage>11</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/1477-7525-12-100</pub-id>
<pub-id pub-id-type="pmid">24925310</pub-id>
</mixed-citation></ref><ref id="pone.0295934.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Torrance</surname><given-names>GW</given-names></name>, <name><surname>Feeny</surname><given-names>D</given-names></name>, <name><surname>Furlong</surname><given-names>W</given-names></name>. <article-title>Visual Analog Scales: Do they have a role in the measurement of preferences for health states? Theory of visual analog scaling</article-title>. <source>Medical Decision Making</source>. <year>2001</year>;<volume>21</volume>: <fpage>329</fpage>&#x02013;<lpage>334</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1177/0272989X0102100408</pub-id>
<pub-id pub-id-type="pmid">11475389</pub-id>
</mixed-citation></ref><ref id="pone.0295934.ref041"><label>41</label><mixed-citation publication-type="book"><name><surname>Krabbe</surname><given-names>PFM</given-names></name>. <source>The measurement of health and health status: Concepts, methods, and applications from a multidisciplinary perpective</source>. <publisher-loc>San Diego</publisher-loc>: <publisher-name>Elsevier/Academic Press</publisher-name>; <year>2016</year>.</mixed-citation></ref><ref id="pone.0295934.ref042"><label>42</label><mixed-citation publication-type="journal"><collab>American Diabetes Association</collab>. <article-title>Standards of medical care in diabetes 2019</article-title>. <source>Diabetes Care</source>. <year>2019</year>;<volume>42</volume>: <fpage>S13</fpage>&#x02013;<lpage>S18</lpage>. Available: <ext-link xlink:href="https://care.diabetesjournals.org/content/42/Supplement_1" ext-link-type="uri">https://care.diabetesjournals.org/content/42/Supplement_1</ext-link><pub-id pub-id-type="pmid">30559228</pub-id>
</mixed-citation></ref><ref id="pone.0295934.ref043"><label>43</label><mixed-citation publication-type="other">Indonesia Ministry of Health. National basic health survey. Diabetes Mellitus. Jakarta: Indonesia Ministry of Health; 2018. Available: <ext-link xlink:href="http://labdata.litbang.kemkes.go.id/images/download/laporan/RKD/2018/Laporan_Nasional_RKD2018_FINAL.pdf" ext-link-type="uri">http://labdata.litbang.kemkes.go.id/images/download/laporan/RKD/2018/Laporan_Nasional_RKD2018_FINAL.pdf</ext-link></mixed-citation></ref><ref id="pone.0295934.ref044"><label>44</label><mixed-citation publication-type="other">BPS-Statistics Indonesia. Jumlah penduduk menurut kelompok umur dan jenis kelamin, 2019. [cited 6 Sep 2023]. Available: <ext-link xlink:href="https://www.bps.go.id/indikator/indikator/view_data_pub/0000/api_pub/YW40a21pdTU1cnJxOGt6dm43ZEdoZz09/da_03/4" ext-link-type="uri">https://www.bps.go.id/indikator/indikator/view_data_pub/0000/api_pub/YW40a21pdTU1cnJxOGt6dm43ZEdoZz09/da_03/4</ext-link></mixed-citation></ref><ref id="pone.0295934.ref045"><label>45</label><mixed-citation publication-type="journal"><name><surname>Crosby</surname><given-names>RD</given-names></name>, <name><surname>Kolotkin</surname><given-names>RL</given-names></name>, <name><surname>Williams</surname><given-names>GR</given-names></name>. <article-title>Defining clinically meaningful change in health-related quality of life</article-title>. <source>J Clin Epidemiol</source>. <year>2003</year>;<volume>56</volume>: <fpage>395</fpage>&#x02013;<lpage>407</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/s0895-4356(03)00044-1</pub-id>
<pub-id pub-id-type="pmid">12812812</pub-id>
</mixed-citation></ref></ref-list></back></article>
